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Summary  
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder among the 
elderly. Amyloid-β is thought to be one of the causative factors for AD, which is produced 
by BACE1 (Beta-secretase) initiated sequential proteolytic cleavage of APP. BACE1 
inhibition is one of the promising therapeutic approaches for AD. Currently, several 
BACE1 inhibitors are undergoing Phase 2/3 clinical trials. However, prolonged BACE1 
inhibition interferes structural and functional synaptic plasticity in mice, most likely due to 
the interrupted metabolism of BACE1 substrates. Seizure protein 6 (SEZ6) is 
predominantly cleaved by BACE1. Furthermore, Sez6 null mice share some phenotype 
with BACE1-inhibited mice including reduced dendritic spine density in cortex and 
diminished performance in hippocampal-dependent behavioral tests.  
In order to shed more light on the function of SEZ6, we analyzed the dendritic spine 
structure and synaptic plasticity in constitutive (Sez6-/-:GFP-M) and conditional 
(Sez6cKO/cKO:SlickV) Sez6 KO mice. In vivo two photon microscopy data showed that lack 
of SEZ6 induces a dose dependent alteration of dendritic spine density and morphology 
in adult mice. To rule out developmental deficits and identify which SEZ6 proteolytic 
fragments are involved we monitored spine density in Sez6cKO/cKO:SlickV mice. The 
tamoxifen-inducible recombinase CreERT2 and eYFP are co-expressed in a small subset 
of neurons in SlickV mice. By applying tamoxifen, Sez6 was knockout specifically in eYFP 
positive neurons in adult mice. It caused a small but significant spine density reduction. 
Electrophysiological field recordings in hippocampus CA1 region showed that SEZ6 is 
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involved in synaptic transmission and LTP mainly due to post-synaptic mechanism. To 
study the dendritic spine plasticity in Sez6-/-:GFP-M mice, we repeatedly imaged the 
apical tufts of layer V pyramidal neurons in the cerebral cortex in both normal condition 
and environmental enrichment condition by intravital two-photon microscopy. Sez6-/- mice 
does not show alerted dendritic spine plasticity in base line condition, but they have 
deficits in conditions that boost spine plasticity like environmental enrichment.  
Then, we investigated whether SEZ6 is involved in BACE1-inhibition-induced synaptic 
alteration. We applied a diet mixed with NB-360 to Sez6-/-:GFP-M and Sez6cKO/cKO:SlickV 
mice. NB-360 is a novel blood-brain barrier penetrable BACE1 inhibitor. Immunoblotting 
analysis showed that NB-360 strongly suppressed SEZ6 and APP cleavage similar to 
Bace1 knockout. To study the impact of long-term pharmacological inhibition of BACE1 
in Sez6-/-:GFP-M mice, we repeatedly imaged the apical tufts of layer V pyramidal 
neurons in the cerebral cortex for 7 weeks using intravital two-photon microscopy. 
Although 3-week treatment of NB-360 caused a significant but reversible reduction of 
density of total dendritic spines, persistent spines (persisting ⩾ 7 days) and new gained 
spines in control mice, the same treatment did not affect dendritic spine dynamics in Sez6-
/-:GFP-M mice. To rule out developmental deficits, we monitored spine dynamics upon 
NB-360 treatment in Sez6cKO/cKO:SlickV mice. Chronic NB-360 treatment did not alter 
spine plasticity in the neurons lacking cell-autonomous SEZ6. Finally, 
electrophysiological field recordings in hippocampal CA1 region showed that LTP is 
reduced in chronic NB-360 treated WT mice and vehicle treated Sez6-/- mice, but NB-360 
treatment did not interfere with LTP in Sez6-/- mice.  
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Our data suggest that SEZ6 has a pivotal role in maintaining normal dendritic spine 
structure and function. Furthermore, SEZ6 is involved in BACE1-inhibitor-induced 
structural and functional synaptic alterations.  
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INTRODUCTION  
1. Alzheimer’s disease 
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease. The first case 
of Alzheimer's disease was reported by German psychiatrist Dr. Alois Alzheimer in 1906 
at the 37th meeting of the Society of Southwest German Psychiatrists (Caselli et al., 2006; 
Reiman, 2006; Selkoe, 2001). Alzheimer's disease is named after him. AD is the cause 
of 60% to 70% of cases of dementia (Prince et al., 2015). It is a progressive age-related 
disease which develops over several years. There is no effective medical treatment or 
preventive approach available for patients until now.  
The typical clinical symptoms of AD are gradual loss of memory and cognitive ability. It is 
due to the destruction of nerve cells and neural connections which leads to atrophy of the 
cerebral cortex and hippocampus and an enlargement of ventricles (Götz et al., 2001; 
Hardy and Selkoe, 2002; Selkoe and Hardy, 2016; Serrano-Pozo et al., 2011). Three 
disease progression stages can generally be distinguished. This disease begins with mild 
cognitive impairment, like the episodic memory dysfunction, which is common in most 
Alzheimer's patients. In the middle stage, cognitive abilities such as orientation, language, 
problem solving, and spatial perception are reduced. In the severe stage, AD patients 
almost lost all cognitive abilities, and they are mentally and physically dependent on their 
caretaker (Jucker et al., 2006; Tarawneh and Holtzman, 2012). 
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Neuritic plaques and neurofibrillary tangles (NFTs) are the two typical neuropathological 
hallmarks of AD (Figure 1) (Hardy and Selkoe, 2002; Selkoe and Hardy, 2016). Neuritic 
plaques are formed by misfolded Amyloid-β peptide (Aβ). Aβ peptide is 36-43 amino acids 
long. The common theory is certain misfolding Aβ molecules served as seeds which 
induce misfolding of other Aβ molecules and oligomerize. These Aβ continually form Aβ 
fiber like a chain reaction akin to a prion infection (McLaurin et al., 2000; Takahashi et al., 
2017; Wetzel et al., 2007). NFTs are formed by aggregated insoluble 
hyperphosphorylated tau protein. In physiological condition, Tau is a highly soluble 
microtubule-associated protein. In human, Tau proteins have six isoforms from 352-441 
amino acids. All the six isoforms can be hyperphosphorylated and present in NFTs (Iqbal 
et al., 2016; Ma et al., 2017). Tangles are also found in numerous of other diseases known 
as tauopathies (Iqbal et al., 2016). Both Neuritic plaques and NFTs are visible in light 
microscopy using various staining techniques, e.g. silver, Congo red and Thioflavin S 
(Figure 1). 
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Figure 1: The histopathological characteristics of the first Alzheimer's patient 
(A) The brain autopsies of the first Alzheimer's disease patient, Auguste Deter. Preserved 
in Center for Neuropathology and Prion Research at the Ludwig-Maximilians-University 
Munich. (B-D) Microimages of Bielschowsky’s silver staining. (B) The over view image of 
two pathological hall mark of Alzheimer's disease. (C-D) Enlarged image of neuritic 
plaques and neurofibrillary tangles. (Kindly provide by Prof. Dr. h.c. Hans Kretzschmar 
and Dr. Burgold) 
 
1.1. The amyloid cascade hypothesis 
The exact cause for AD is not yet clear. In 1991, the amyloid cascade hypothesis 
synthesized the knowledges from histopathological and genetic studies and proposed 
that deposition of the Aβ peptide in the human brain is the initiative and crucial step 
leading to AD (Hardy and Allsop, 1991; Karran et al., 2011).  
Aβ is the sequential proteolytic cleavage product of amyloid precursor protein (APP), a 
type-I trans-membrane protein. The N-terminus of APP is within the lumen/extracellular 
space and the C-terminus is within the cytosol. APP is proteolytically processed at several 
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different subcellular sites, for example Golgi apparatus and transport vesicles. APP can 
be processed by many secretases including α-secretase (A Disintegrin and 
metalloproteinase domain-containing protein 10, ADAM10), β-secretase (beta-site 
amyloid precursor protein cleaving enzyme 1, BACE1), γ-secretase complex and recently 
discovered η-secretase (e.g. membrane-type 5 matrix metalloproteinase, MT5-MMP) 
(Figure 2A). APP processing can be classified into non-amyloidogenic pathway (Figure 
2B), amyloidogenic pathway (Figure 2C) and η-secretase pathway (Figure 2D-E) (Haass, 
2004; Willem et al., 2015).  
The non-amyloidogenic pathway is considered as the physiologically normal pathway 
which prevents Aβ generation (Haass et al., 1992, 1993). In this pathway, APP is first 
cleaved by α-secretase in the approximately middle of the Aβ region, releasing a large 
part of the ectodomain (sAPPα) into the lumen or extracellular space. The subsequent γ-
secretase complex processing of the trans-membrane C-terminal fragment (CTFα or c83) 
generates nontoxic P3 fragment and APP intracellular fragment (AICD) (Figure 2B).  
In the amyloidogenic processing of APP, which leads to generation of the toxic Aβ, is 
dependent on consecutive action of BACE1 and γ-secretase complex. Shedding by 
BACE1, APP generates another large part of the ectodomain (sAPPβ) and APP C-
terminal fragment (CTFβ or c99). Then the γ-secretase complex performs intramembrane 
proteolysis within the biological membrane releasing Aβ and AICD. (Figure 2C).  
The η-secretase pathway is reported recently as a new physiological APP processing 
pathway (Willem et al., 2015). The initiating enzyme of η-secretase pathway is 
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membrane-bound matrix metalloproteinases (e.g. MT5-MMP). CTF-η, the third type of 
large ectodomain fragment, is generated after MT5-MMP proteolysis. CTF-η is continually 
processed by α- and β-secretase and releasing Aη-α and Aη-β, respectively (Figure 2D-
E). 
 
Figure 2: Schematic representation of amyloid precursor protein sequential 
cleavage 
(A) APP is a type I trans-membrane protein. It can be processed by α-, β-, γ- and η-
secretases. (B) In the non-amyloidogenic pathway, APP is first cleaved by α-secretases 
and released sAPPα into the extracellular space. The subsequent γ-secretase processing 
of the trans-membrane C-terminal fragment (CTFα, c83) generates nontoxic P3 fragment 
and APP intracellular fragment (AICD). (C) The amyloidogenic processing of APP is 
independent on β-secretases, resulting sAPPβ and CTFβ (c99). The toxic β-amyloid 
peptide (Aβ) is released by γ-secretases. (D-E) In the recent reported η-secretase 
pathway, APP is processed by η-secretase follow by α- and β-secretases and releasing 
Aη-α and Aη-β, respectively. 
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2. BACE1  
BACE1 is a typical transmembrane aspartic protease with a luminal active site which 
sheds the ectodomain of membrane proteins (Yan et al., 1999). It is mainly expressed in 
the central nervous system (CNS), including the neocortex and hippocampus. BACE1 
has more than 35 substrates, including APP, SEZ6, and CHL1 (Kuhn et al., 2012; Pigoni 
et al., 2016; Vassar et al., 1999; Yan et al., 1999; Zhou et al., 2012). Under physiological 
condition, BACE1 substrates are processed in acidic compartments, such as trans-Golgi 
network and endosome, where BACE1 displays its maximum proteolytic activity 
(Kalvodova et al., 2005; Vassar et al., 2014).  
BACE1 is the sole enzyme for initiating Aβ generation, and it is the rate limiting enzyme 
of the amyloidogenic pathway (Ghosh and Osswald, 2014; Sinha and Lieberburg, 1999; 
Vassar, 2016; Vassar et al., 1999). Knockout of Bace1 almost completely abolishes Aβ 
production in transgenic APP mouse models (Roberds et al., 2001; Vassar et al., 1999). 
The value of BACE1 as therapeutic target is further supported by the finding that the 
Icelandic mutation, APPAla673Thr, which suppresses APP cleavage by BACE1, results 
roughly in a 20-40% reduction of Aβ and protects against AD (Jonsson et al., 2012).  
The transportation of BACE1 within neurites is via trafficking vesicles. For the anterograde 
axonal transport, BACE1 is co-transferred together with APP regulating by calsyntenin-1 
and Rab11 (Buggia-Prévot et al., 2014; Steuble et al., 2012). Under physiological 
conditions, APP is cleaved by BACE1 in these vesicles (Del Prete et al., 2014). The 
retrograde trafficking of BACE1 is regulated by Vps35 in both axons and dendrites (Wang 
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et al., 2012). A recent report using fluorescence labeled technique demonstrated that 
BACE1 is located at both pre- and post-synaptic compartments within neurons (Das et 
al., 2016), indicating BACE1 has important function in the synapse. BACE1 also 
accumulates at amyloid plaque in axonal dystrophies in both AD mouse models and 
patients (Blazquez-Llorca et al., 2017; Kandalepas et al., 2013). It might directly facilitate 
the local generation of Aβ; hence further promoting the amyloid deposition. 
2.1. BACE1 inhibitor 
In the past decades, both academia and industry invested a lot of resources for 
developing BACE1 inhibitors. The 1st generation of BACE1 inhibitors are peptidomimetic 
molecules (Kandalepas and Vassar, 2014; Sinha et al., 1999). These peptide-based 
molecules mimic the β-site of APP and replaces it with a non-cleavable amide (Vassar, 
2016). Although peptide-based BACE1 inhibitors strongly inhibit BACE1 in vitro, they do 
not have the properties to in vivo application, e.g. oral bioavailability, long serum half-life, 
or blood-brain barrier (BBB) penetrable. The 2nd generation of BACE1 inhibitors are 
developed based on the X-ray crystal structure of BACE1 (Durham and Shepherd, 2006; 
Hong et al., 2002). These inhibitors are small molecular weight chemical compounds 
which can be applied orally and are plasma membrane and BBB penetrable. However, 
the concentrations in the brain are still low (Vassar, 2014, 2016). The 3rd generation of 
BACE1 inhibitors exhibit satisfactory brain concentration and strong inhibition of BACE1 
proteolytic activity. Several of the 3rd generation BACE1 inhibitors are in different phases 
of clinical trials. Some of these compounds showed promising results in phase 1 trials, 
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which did not show severe reveal adverse effects and very effectively reduce Aβ reduction 
in a dosage-dependent manner. Currently, at least 6 of them are being tested in phase 
2/3 trials (Table 1). 
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 Table 1: O
ngoing B
A
C
E1 inhibitors in clinical trials 
C
om
pound 
com
pany 
C
linical 
trial stage 
N
C
T 
num
ber 
D
osages 
A
β R
eduction 
# 
Patient 
population 
Expected 
com
pletion 
years 
C
N
P520 
N
ovartis 
Am
gen, 
Phase 2/3 
02565511 
03131453 
50m
g 
15/50m
g 
-60%
 (10m
g) 
-80%
 (35m
g) 
Asym
ptom
atic 
at-risk patients 
(APO
E4) 
2023 
2024 
A
ZD
3293 
(LY3314814) 
Eli Lilly, 
AstraZeneca 
Phase 2/3 
02783573 
02972658 
02245737 
03019549 
  
20/50m
g 
 
-50%
 (15m
g) 
-80%
 (50m
g) 
Early and m
ild 
AD
 
2021 
2020 
2019 
2017 
LY3202626 
Eli Lilly 
Phase 2 
02791191 
 
-50%
 (1m
g) 
M
ild AD
 
2019 
Elenbecestat 
(E2609) 
Eisai, 
Biogen 
Phase 2/3 
02322021 
03036280 
02956486 
  50m
g 
-50%
 (5m
g) 
-80%
 (50m
g) 
Early AD
 
2020 
2020 
2020 
JN
J-
54861911 
Janssen 
Phase 2/3 
02569398 
02406027 
5/25m
g 
5/10/25m
g 
-50%
 (5m
g) 
-80%
 (25m
g) 
Asym
ptom
atic 
at-risk patients 
and Early AD
 
2023 
2022 
M
K
-8931 
M
erck 
Phase 2/3 
Phase 3 
01739348 
01953601 
12/40/60m
g 
12/40m
g 
-32%
 (10m
g) 
-80%
 (40m
g) 
Prodrom
al AD
 
2017* 
2021 
N
C
T num
bers refer to the study codes in the C
linicalTrials.gov database 
# D
ata from
 pre-clinical hum
an studies or phase 1 studies. 
* Term
inated at A
pril 2017 
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2.2. BACE1 has physiological functions at the synapse  
BACE1 has many physiological substrates, indicating it is involved in various functions. 
The knockout of Bace1 leads to a number of physiological and behavioral deficits in mice, 
including increased astrogenesis and decreased number of mature neurons (Hu et al., 
2013), impaired axon myelination during development (Hu et al., 2006), axon guidance 
errors in the olfactory bulb and hippocampus (Hitt et al., 2012; Rajapaksha et al., 2011), 
impaired remyelination in injured sciatic nerves in the adult mice (Hu et al., 2015), reduced 
number of muscle spindles resulting in a swaying walking pattern (Cheret et al., 2013), 
as well as decreased anxiety (Laird et al., 2005). Most likely, BACE1 is involved in these 
physiological functions via its substrates. In the last decade, more than 35 BACE1 
substrates have been identified (Dislich et al., 2015; Kuhn et al., 2012; Zhou et al., 2012). 
Among those substrates, some of them are located at the synapse which are known to 
be of critical importance for synaptic function and plasticity (Table 2).  
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 Table 2: B
A
C
E1 substrates involved in synaptic plasticity 
B
A
C
E1 
cleavage  N
am
e 
Localization 
Phenotypes / Functions 
R
ef. 
H
igh 
Seizure protein gene 
6 (SEZ6) 
D
endrite, D
endritic 
spine 
Abnorm
al dendritic arborization, 
reduced dendritic spine density, 
synaptic transm
ission and LTP 
(G
unnersen et al., 
2007; Zhu et al., 
2018) 
 
Am
yloid precursor-
like protein 1 
(APLP1) 
Pre- and post-
synapse 
R
educed synaptogenesis, dendritic 
spine density  
(Schilling et al., 
2017) 
 
C
lose hom
ologue of 
L1 (C
H
L1)  
Axon, Presynaptic 
boutons 
Axon guidance defects 
(C
ao et al., 2012; 
R
ajapaksha et al., 
2011) 
 
N
euroligin 4 
(N
LG
N
4) 
G
lycinergic post-
synapses 
Affects synaptic transm
ission 
(H
oon et al., 2011) 
 
N
euroligin 2 
(N
LG
N
2) 
Inhibitory synapses 
Affects synaptic transm
ission 
(N
guyen et al., 
2016) 
 
C
ontactin 2 
Axon, Presynaptic 
boutons 
Axon guidance defects 
(G
autam
 et al., 
2014) 
 
Am
yloid precursor 
protein (APP) 
Pre- and post-
synapse 
Increased prim
ary dendrites, Im
paired 
dendritic spine m
orphology, density and 
dynam
ic 
(W
eyer et al., 
2014) 
Low
 
N
euroligin 1 
(N
LG
N
1) 
D
endritic spine of 
excitatory synapses 
R
educed N
M
D
AR
-m
ediated synaptic 
transm
ission and LTP 
(Jiang et al., 2017; 
Song et al., 1999) 
? 
N
euregulin 1 (N
R
G
1) 
Axon, Presynaptic 
boutons 
H
yperactivity, hypom
yelination, reduced 
dendritic spine density 
(H
u et al., 2010; 
Savonenko et al., 
2008) 
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2.2.1. BACE1 and synaptic structures 
A synapse is a junction formed between two neurons, which transmits electrical or 
chemical signals from one to the other. The postsynaptic compartment of excitatory 
synapses, the dendritic spine, is a plastic structure that can change its shape within 
minutes or present over longer spans of weeks to months, which is termed structural 
plasticity (Fu and Zuo, 2011; Lendvai et al., 2000; Yang et al., 2009). Increased spine 
formation and stabilization is associated with learning and memory (Yang et al., 2009). 
Impairments of synaptic structure and plasticity is thought to be one of the most important 
mechanisms for memory loss in dementia (Herms and Dorostkar, 2016).  
As mentioned above, BACE1 is located at pre-synaptic terminals, especially enriched in 
mossy fiber terminals (Hitt et al., 2012; Kandalepas et al., 2013). In Bace1-/- mice, the 
mossy fiber terminals have normal ultrastructure (Kandalepas et al., 2013), however the 
infrapyramidal bundle of mossy fibers is significantly shorter indicating a potential 
alteration in axonal outgrowth (Gautam et al., 2014; Hitt et al., 2012). The abnormal 
axonal growth might be due to reduced β-cleavage of contactin-2, a cell adhesion 
molecule, since contactin-2 plays an important role in regulating axon guidance and path 
finding (Furley et al., 1990; Gautam et al., 2014). Abnormal axonal growth cone collapse 
has been seen in both Bace1-/- or BACE1 inhibitor treated mice (Barão et al., 2015; Cao 
et al., 2012; Rajapaksha et al., 2011). The altered function of the neural cell adhesion 
molecule close homolog of L1 (CHL1) has been supposed to be involved in this process, 
too (Naus et al., 2004). Cleavage of CHL1 by BACE1 generates N-terminal fragment 
-16-	
 
(CHL1-NTFβ) (Kuhn et al., 2012), which is critical for growth cone collapse in thalamic 
neurons since CHL1-NTFβ interacts with semaphorin 3A (Sema3A) (Barão et al., 2015). 
BACE1 is also located within dendritic spines. The density and plasticity of dendritic 
spines in Bace1-/- and Bace1+/- mice as well as WT mice treated with BACE1 inhibitors 
has been studied by various groups (Devi and Ohno, 2015; Filser et al., 2015; Sadleir et 
al., 2015; Zhu et al., 2018; Zou et al., 2016). The total spine density is significantly reduced 
in the CA1 region of Bace1-/- mice (Savonenko et al., 2008). Moreover, the proportion of 
mushroom spines is also significantly lower. This is concurrent with the reduction of 
PSD95 (post-synaptic density protein 95) density (Savonenko et al., 2008). These 
changes might be the consequences of an altered BACE1-dependent NRG1 (neuregulin-
1) signaling. Indeed, NRG1 accumulation is known to cause a reduction in dendritic spine 
density by altering the interaction between ErbB4 (receptor tyrosine-protein kinase erbB-
4) and PSD95 (Hu et al., 2006; Willem et al., 2006). Dendritic spine plasticity has not yet 
been studied in Bace1-/- mice. However, in adult Bace1+/- mice, there is no evidence 
showing that dendritic spine plasticity is impaired under enriched environment condition, 
a method for boosting spine turnover (Zou et al., 2016). 
Given that the BACE1 protein level is highest during early postnatal development in mice 
(Willem et al., 2006), developmental deficit might cause certain structural changes at 
synapses indirectly. Especially, observations in constitutive knock-out mice are based on 
life-long absents of BACE1 protein in the brain were compensation may mask the effect 
of an acute loss of BACE1 function at the synapse. Therefore, it is necessary to validate 
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the effects of BACE1 inhibition during adulthood, as some side effects may limit its clinical 
application. 
Several non-peptidic BACE1 inhibitors of different structures like SCH1682496 
(Merck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania) (Stamford et al., 
2012), LY2811376 (Eli Lilly and Company, Indianapolis, Indiana) (May et al., 2011) and 
β-Secretase Inhibitor IV (Stachel et al., 2004) have been developed within the last 
decade. All of these inhibitors strongly suppress Aβ production in mice (Filser et al., 2015; 
Kamikubo et al., 2017; May et al., 2011) and human (60). Using in vivo sequential 
microscopy, the effect of these inhibitors on individual dendritic spines has been studied 
in GFP-M mice. Administration of SCH1682496 (16 days, 100 mg/kg/day) or LY2811376 
(16 days, 100 mg/kg/day) was found to reduce the overall density of dendritic spines, and 
lower the formation rate of new gained spines in GFP-M mice (Figure 3) (Filser et al., 
2015). These impairments were not seen at lower doses (SCH1682496 or LY2811376, 
30mg/kg/day) (Filser et al., 2015). Similar findings were obtained in cultured brain slices 
after β-Secretase inhibitor IV treatment (Kamikubo et al., 2017). The treatment was found 
to decrease the protein level of PSD95 during 3-17 days in vitro (DIV) (Kamikubo et al., 
2017). Therefore, BACE1 proteolytic activity is important for maintaining the normal 
synaptic formation and maturation processes. 
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Figure 3: BACE1 inhibitor alters dendritic spine plasticity in adult GFP-M mice 
(A) the layer V cortical neurons were labeled with eGFP in GFP-M mice. Their apical 
dendrites were imaged for 45 days. BACE1 inhibitor SCH1682496 was applied to mice 
from day 10 and over 16 days (every 12 hours). Two dosage, 30 mg/kg and 100mg/kg, 
were used. White arrowheads: stable spines. green arrowheads: new gained spines. 
magenta arrowheads: lost spines. Scale bar: 10 μm. (B) Quantification of relative spine 
density, new gained and lost spines. 4-5 animals per group,10 dendrites per animal. Error 
bars represent S.E.M. One-way analysis of variance. ** p<0.01; *** p<0.001; (Filser et al., 
2015). 
 
2.2.2. BACE1 and synaptic function 
Structural alterations of synapses are considered as an indicator for functional changes. 
But how is BACE1 involved in neuronal function is not yet fully clear. Bace1-/- mice do not 
show any alterations in basal synaptic transmission under low stimulation intensity in 
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hippocampus CA1 (Figure 4A) (Filser et al., 2015; Laird et al., 2005). However, when 
using higher stimulation intensities, the slope of the stimulus-response response curve 
was significantly lower compared to controls (Filser et al., 2015). In line with knockout 
mouse model, various BACE1 inhibitors (SCH1682496 and LY2811376 and C3) were 
able to decrease the slope of the stimulus-response curve over a wide range of intensities 
in both mice and rat, indicating the weakening of synaptic transmission upon BACE1 
inhibition (Filser et al., 2015; Kamikubo et al., 2017). 
BACE1 regulates the surface expression of voltage-gated sodium channels, the key 
player for generating action potentials, by cleaving the β-subunits (Navβ2) (Wong et al., 
2005). However, controversy observations have been obtained in Bace1-/- mice: Hitt et 
al. reported that the expression level of NaV1.2 is not altered in CA3 pyramidal neurons 
of Bace1-/- mice (Hitt et al., 2010). Hu et al. , however, showed that the expression level 
of NaV1.2 is strongly increased (Hu et al., 2010). Using whole cell recordings, Dominguez 
et al. showed that Na+ current densities are lower in cortical pyramidal neurons of Bace1-
/- mice (P23-30) (Dominguez et al., 2005), but Kim at al. reported that Na+ current 
densities in CA1 neurons is reduced in BACE1 overexpression mice (Kim et al., 2007). 
Hu et al. data support the notion that Na+ currents are significantly greater in hippocampal 
pyramidal neurons of Bace1-/- mice (P21-30) (Hu et al., 2010). These data suggest that 
BACE1 might affect neuronal activity by regulating the surface expression and function 
of voltage-gated sodium channels. 
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Hippocampal LTP (long-term potentiation) and LTD (depression) are the two commonly 
used paradigms of studying synaptic plasticity. Both LTP and LTD are activity-dependent 
strengthening or weakening in the efficacy of synapses, respectively (Lynch, 2004). 
These synaptic modifications are supposed to share the same cellular mechanisms that 
underlay learning and memory (Llinás et al., 1997; Nicoll, 2017). LTD seems not to be 
significantly altered in Bace1-/- mice: It is not altered in Schaffer collateral-CA1 pathway 
(Laird et al., 2005) and in mossy fiber-CA3 pathway a slight enlargement has been 
described (Wang et al., 2008). However, in LTP the situation is different: Using theta-
burst stimulation (TBS) protocol, Bace1-/- mice show a slight but not significant LTP 
reduction in Schaffer collateral-CA1 pathway (Laird et al., 2005). This attenuation is more 
noticeable by using high frequency stimulation (HFS) protocol (Figure 4B) (Filser et al., 
2015). The mossy fiber LTP is also impaired in Bace1-/- mice (Wang et al., 2014). 
Interestingly, activation of α7nAChR (α7 nicotinic acetylcholine receptor) by nicotine has 
been shown to restore LTP in Bace1-/- mice (Wang et al., 2010). Since α7nAChR is 
involved in NMDA receptor dependent hippocampal LTP by regulating astrocytic release 
of D-serine, the NMDA receptor co-agonist (Papouin et al., 2017), it would be interesting 
to study whether BACE1 regulates D-serine homeostasis. Impaired LTP also has been 
observed in chronic strong BACE1 inhibition in WT mouse (Filser et al., 2015; Zhu et al., 
2018). Even pre-exposure to a single oral dose of SCH1682496 attenuates LTP (Willem 
et al., 2015). Intriguingly, LTP attenuation after BACE1 inhibition is clearly dose depended 
(Figure 4B) (Filser et al., 2015). Moreover, Bace1+/- mice have a normal Schaffer 
collateral-CA1 LTP (Giusti-Rodríguez et al., 2011; Wang et al., 2014). This indicates that 
synaptic deficits can be avoided if the dosage of BACE1 inhibitor does not reduce its 
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function by more than 50%. Consistent with reduced LTP, Bace1-/- and BACE1 inhibited 
mice, show deficits in hippocampus-dependent cognitive and emotional memory tests, 
but Bace1+/- mice behave normally (Dominguez et al., 2005; Filser et al., 2015; Kimura et 
al., 2010; Ohno et al., 2004, 2007; Savonenko et al., 2008; Weber et al., 2017).  
 
Figure 4: BACE1 inhibitor SCH1682496 attenuates synaptic transmission and long-
term potentiation in CA1 neurons 
(A) stimulus-response relationship graphs from WT mice treated with vehicle or 100 
mg/kg of SCH1682496 and vehicle treated Bace1-/- mice. (B) Summary plots of fEPSP 
slope changes during baseline recording and after induction of long-term potentiation 
from WT mice treated with vehicle, 30 or 100 mg/kg of SCH1682496. This figure is 
adapted from Filser et al. (2015). 
 
Paired-pulse facilitation (PPF) is a sensitive measurement of pre-synaptic vesicular 
release probability (Manabe et al., 1993). This approach was applied to understand how 
BACE1 affects synaptic transmission and LTP. Although the ultrastructure of mossy fiber 
terminals is normal in Bace1-/- mice, it has a significant increased PPF ratio mossy fibers-
CA3 pathway (Kandalepas et al., 2013; Wang et al., 2008). The increased PPF occurs 
specifically at synapses of mossy fiber-CA3 pyramidal neuron. The PPF at mossy fiber-
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CA3 interneurons synapses is normal (Wang et al., 2014). A significantly enlarged PPF 
ratio is also seen in Schaffer collateral-CA1 pathway (Laird et al., 2005). PPF ratio 
remains normal in Bace1+/- mice (Giusti-Rodríguez et al., 2011; Wang et al., 2014). These 
results indicate that complete knockout of Bace1 induces a deficit in pre-synaptic function. 
These results agree with the fact that expression of post-synaptic marker PSD-95, but not 
pre-synaptic marker synaptophysin, changes upon the treatment with the BACE-inhibitor 
IV (Kamikubo et al., 2017). 
The functions of BACE1 in maintaining dendritic spine structure, synaptic transmission, 
as well as both short-term and long-term plasticity cannot be ignored (Table 3). However, 
all on-target side effects, which are seen in Bace1-/- and mice treated with high dose of 
BACE1 inhibitor, are largely prevented in Bace1+/- mice (50% reduction in BACE1 protein 
level) or low dose treatment. Therefore, the careful adjustment of the dosage of certain 
BACE1 inhibitor might be crucial for the success of these compounds in the treatment of 
AD. 
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 Table 3: Consequences of genetically knockout B
ace1 and pharm
acologically inhibits B
A
C
E1 on synapses 
 
 
B
ace1
-/- 
B
ace1
+/- 
B
A
C
E1 
inhibition 
R
ef. 
Synaptic 
structure 
Pre-synaptic 
term
inals 
N
orm
al in 
m
ossy fiber 
term
inals 
 
 
(Kandalepas et al., 2013) 
Spine D
ensity 
R
educed in 
C
A1 
 
R
educed in 
cortical L5 
pyram
idal 
neurons 
(Filser et al., 2015; Savonenko et 
al., 2008; Zhu et al., 2018) 
Spine Plasticity 
 
N
orm
al adaptive 
plasticity in 
cortical L5 
neurons 
Im
paired in 
cortical L5 
pyram
idal 
neurons 
(Filser et al., 2015; Zhu et al., 
2018; Zou et al., 2016) 
Synaptic 
function 
B
asal synaptic 
transm
ission 
R
educed in 
C
A1 
N
orm
al in C
A1 
R
educed in C
A1 
(Filser et al., 2015; G
iusti-
R
odríguez et al., 2011; Kam
ikubo 
et al., 2017) 
Pre-synaptic 
function 
Increased in 
C
A1 & C
A3 
N
orm
al in C
A1 & 
C
A3 
N
orm
al in C
A1 
(G
iusti-R
odríguez et al., 2011; 
Kandalepas et al., 2013; W
ang et 
al., 2008, 2014; Zhu et al., 2018) 
LTP 
R
educed in 
C
A1 & C
A3 
N
orm
al in C
A1 & 
C
A3 
R
educed in C
A1 
(Filser et al., 2015; G
iusti-
R
odríguez et al., 2011; Kam
ikubo 
et al., 2017; W
ang et al., 2014; 
Zhu et al., 2018) 
LTD 
N
orm
al in 
C
A1; 
Slight deficits 
in C
A3 
 
 
(Laird et al., 2005; W
ang et al., 
2008) 
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2.3. Long-term inhibition of BACE1 in AD mouse models 
The effects of knocking out Bace1 in AD mouse model are promising. Homozygous 
knockout of Bace1 mice almost completely abolishes the generation of toxic Aβ peptides 
and amyloid plaques formation in various AD mice models (McConlogue et al., 2007; 
Roberds et al., 2001; Sadleir et al., 2015). Even partially reduction of BACE1 protein in 
AD mice model (5XFAD:Bace1+/-) could significantly reduce the Aβ production and plaque 
load in female animals (Devi and Ohno, 2015; Sadleir et al., 2015). 
2.3.1. BACE1 inhibition on Aβ induced impaired spine plasticity  
Amyloid plaque deposition is the main pathological hallmark of Alzheimer's disease 
(Hardy and Selkoe, 2002). During the formation of amyloid plaques, dendritic spine 
density reduces in vicinity of Aβ deposition in various of AD mouse models, including 
APP/PS1, Tg2576 and AppNL-G-F mice (Bittner et al., 2012; Dorostkar et al., 2014; Saito 
et al., 2014). In areas in far distance to plaques the density of dendritic spines is not 
changed (Bittner et al., 2012; Dorostkar et al., 2014). The reduced spine density is mainly 
due to loss of spine (Bittner et al., 2012). It might due to strongly increased synaptic 
pruning via over activated microglia induced by complement protein-related pathway 
(Hong et al., 2016a). Aβ recruits complement C1q complex and C3 to synapses, and C3 
mediates synapse elimination by phagocytic glia cells (Hong et al., 2016a). It is 
reasonable to speculate that lowering Aβ by BACE1 inhibition could rescue spine loss at 
plaques in AD mouse models.  
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2.3.2. Functional effect of BACE1 inhibition on AD pathophysiology 
One of the typical electrophysiological consequences of accumulated Aβ is impaired 
synaptic plasticity in a dose dependent manner (Puzzo et al., 2008; Rammes et al., 2017). 
PPF is normal in APP/PS1 mice and APPV717I transgenic mice(Chong et al., 2011; 
Gengler et al., 2010; Viana da Silva et al., 2016), and slightly increased in 3xTgAD mice 
(Davis et al., 2014). Several AD mouse models display an attenuated hippocampal LTP 
alteration started from 6-12 month of age (Gengler et al., 2010; Kimura and Ohno, 2009; 
Ma et al., 2013; Oddo et al., 2003; Roder et al., 2003; Volianskis et al., 2010). Although 
half reduction of BACE1 protein level in 5XFAD mice did not rescue the basal synaptic 
transmission deficits, it rescues the LTP deficit (Kimura et al., 2010). Hippocampus-
dependent fear conditioning task further confirmed that 5XFAD:Bace1+/- mice are rescued 
completely back to wild-type levels (Kimura et al., 2010). Similar effects are reproducible 
using BACE1 inhibitor. Application of BACE1 inhibitor LY2886721 over 3-days (0.2 
nmol/day, Eli Lilly and Company, Indianapolis, Indiana) rescues the in vivo LTP reduction 
in McGill-Thy1-APP-TG rats (Qi et al., 2014).  
3. Seizure protein 6 
SEZ6 (Seizure protein 6), also known as brain specific receptor-like protein C, is first 
reported by Shimizu-Nishikawa and colleagues (Shimizu-Nishikawa et al., 1995a). The 
Sez6 mRNA expression is increased in cultured mice cortical neurons after acute 
Pentylenetetrazol (PTZ) treatment induced bursting activity (Shimizu-Nishikawa et al., 
1995a, 1995b). In mice, knockout of Sez6 does not show increased or decreased 
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sensitivity to PTZ induced clonic seizure (Gunnersen et al., 2007). Further study 
demonstrated that the expression of SEZ6 is regulated by neuronal activity (Rampon et 
al., 2000).  
 
Figure 5: SEZ6 expression level in different age 
Upper: SEZ6 mRNA is about 4 Kb, it is detectable from embryonic day 13 in mouse 
neocortex. Lower: SEZ6 protein level. (Adapted from Kim et al., 2002 and Osaki et al., 
2011) 
 
SEZ6 is a typical type I trans-membrane protein expressed exclusively in cortical and 
hippocampal pyramidal neurons. The expression of SEZ6 starts from embryonic day 13 
and its protein level decreased during postnatal development (Figure 5) (Kim et al., 2002). 
SEZ6 is expressed prominently in deep cortical layers, hippocampal CA1 and the striatum 
(Figure 6) (Osaki et al., 2011). In young mice, SEZ6 is located in the somatodendritic 
compartment, specifically in the dendritic plasma membrane, synaptosomes and 
recycling endosomes (Carrodus et al., 2014; Gunnersen et al., 2007; Mitsui et al., 2013; 
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Shimizu-Nishikawa et al., 1995b). In adult mice, SEZ6 is mainly detecable in the soma of 
pyamidal neurons.  
 
Figure 6: SEZ6 distribution in mouse cortex and hippocampus 
SEZ6 is expressed by neurons. SEZ6 locates in both neurites and soma in young mice. 
In adult mice, SEZ6 is mainly located in the soma of neurons. (A-C) Cerebral cortex; (D-
F) Hippocampus; (A, D) P0; (B, E) P14; (C, F) Adult. I, II/III, IV, V, VI: Cortex layer I, II/III, 
IV, V, VI; cc: corpus callosum; CA1: Cornu Ammonis 1; CA2: Cornu Ammonis 2; CA3: 
Cornu Ammonis 3; DG: dentate gyrus. Bar, 200 μm. (Adapted from Osaki et al., 2011). 
 
3.1. The structural of SEZ6 
The SEZ6 ectodomain has several predicted sub-domains, including 3 CUB (complement 
C3b/C4b binding site) domains and 5 SCR (Short Consensus Repeat) domains (Figure 
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7). These sub-domains are commonly known as protein-protein interaction domains 
which are also found in a variety of cell surface receptors. SCR domain is also known as 
complement control protein module, it exists in a wide variety of complement and 
adhesion proteins, for example complement protein C2 (Krishnan et al., 2009). CUB 
domains are involved in a diverse range of functions, including complement activation. 
These domains imply that SEZ6 might interact with other extracellular or cell-surface 
proteins, and it might have a functional link with complement proteins.  
 
Figure 7: Schematic diagram of microdomains of SEZ6 
SEZ6 has 3 CUB (Complement C1r/C1s, Uegf, Bmp1) domains and 5 SCR (Short 
Consensus Repeats) domains. 
 
3.2. Proteolytic processing of SEZ6 
The full length SEZ6 is exclusively and initially cleaved by BACE1 (Kuhn et al., 2012; 
Pigoni et al., 2016). Similar to the other substrates, BACE1 cuts SEZ6 at the 
juxtamembrane domain between leucine-906 and aspartate-907 (Pigoni et al., 2016), 
-29-	
 
generating a secreted soluble SEZ6 (sSEZ6) fragment and SEZ6 C-terminal 
transmembrane fragment (SEZ6-CTF) (Kuhn et al., 2012; Pigoni et al., 2016). Like other 
substrates, e.g. contactin-2 and CHL1 (close homolog of L1), BACE1 is a negative 
regulator of SEZ6 cell surface level in neurons, indicating BACE1 may be deeply involved 
in the regulation of SEZ6 functions. Then, SEZ6-CTF subsequently cleaved by γ-
secretase, which leads to release of another SEZ6 intracellular domain (SEZ6-ICD) 
(Pigoni et al., 2016). The sSEZ6 is secreted to extracellular matrix, because it is 
detectable in medium and CSF (cerebrospinal fluid) of murine and human (Khoonsari et 
al., 2016; Pigoni et al., 2016).  
 
Figure 8: Schematic diagram of processing of SEZ6 by BACE1 and γ-secreatase 
SEZ6 is a type I trans-membrane protein. SEZ6 is cleaved by BACE1, generating soluble 
SEZ6 and its c-terminal fragments (SEZ6-CTF). γ-secretase subsequently cuts SEZ6-
CTF releasing SEZ6 intracellular domain (SEZ6-ICD). 
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3.3. Function of SEZ6 
SEZ6 has important roles in dendritic development, regulating excitatory synaptic 
connectivity, motor coordination and spatial memory. Knockout Sez6 induces some 
specific deficits in mice. First, knock out Sez6 induces morphological changes in neurons. 
Sez6-/- mice show an increased numbers of short neurites but decreased total neurite 
length (Gunnersen et al., 2007). Results from primary cultured cortical neurons showed 
that full length SEZ6 and soluble SEZ6 have opposite function in regulating neurites 
outgrowth. sSEZ6 strongly increased neurites number, whereas full length SEZ6 slightly 
but significantly decreased neurites number (Gunnersen et al., 2007). Then, the dendritic 
spine density and reduced PSD95 puncta are reduced in somatosensory cortex of 5- to 
7-week-old Sez6-/- mice (Gunnersen et al., 2007). This reduction impairs the connectivity 
between pyramidal neurons from layer II/III to layer V (Gunnersen et al., 2007). Finally, 
these deficits lead to an altered behavior in many tests. For example: 1) Sez6-/- mice 
cover less distance in locomotor tests; 2) Sez6-/- mice spend more time on the open arms 
of the plus maze and in the novel arm of the Y-maze compared with their WT 
counterparts; 3) in the Morris water maze test, Sez6-/- mice perform as normal as WT in 
spatial learning of the hidden platform position, but did not display a preference for the 
target quadrant in probe trials (Gunnersen et al., 2007). 
Two independent groups reported that Sez6 genetically links to febrile seizures and 
epilepsy in human (Mulley et al., 2011; Yu et al., 2007). Furthermore, using whole-exome 
sequencing, mutated Sez6 may be one of the candidates to be involved in the etiology of 
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severe intellectual disability and childhood onset schizophrenia, two severe 
neurodevelopmental disorders of unknown etiology. Three amino acids in SEZ6 (Thr229, 
Thr230 and Thr231) are deleted in childhood onset schizophrenia patients (Ambalavanan 
et al., 2016). One missense mutation is identified in SEZ6 (Arg657Gln) from severe 
intellectual disability patients (Gilissen et al., 2014). Both diseases are diagnosed in 
children, suggesting SEZ6 may have important function in neuronal development.  
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MATERIAL AND METHODS 
1. Animals and housing conditions 
In these experiments, the used mice lines are listed in Table 4. All mice were hold under 
pathogen-free conditions in the animal facility of ZNP (Zentrum für Neuropathologie und 
Prionforschung) of the LMU (Ludwig-Maximilians-Universität München). The room 
temperature was kept at 21 ± 1°C. Mice were group housed up to a maximum of 5 mice 
per cage. All animals had access to food and water ad libitum and were maintained on a 
12h light: 12h dark cycle. Health condition of each animal was checked every day with 
recorded body weight. All animal experimental procedures and protocols were followed 
the regulations of LMU and approved by the government of Upper. 
Table 4: list of mice line 
Mouse line  Origin Ref. 
C57BL/6J  Charles River Laboratories (Sulzfeld, Germany)  
Bace1-/- B6.129-Bace1tm1Pcw/J Jackson Laboratory (Bar Harbor, Maine) (Cai et al., 2001) 
APP-/- B6.129S7-Apptm1Dbo/J Prof. Dr. Ulrike C. Müller (University of Heidelberg) 
(Zheng et al., 
1995) 
SlickV 
B6;SJL-Tg(Thy1-
cre/ERT2,-
EYFP)VGfng/J 
Jackson Laboratory (Bar 
Harbor, Maine) 
(Young et al., 
2008) 
GFP-M Tg(Thy1-eGFP)MJrs Jackson Laboratory (Bar Harbor, Maine) 
(Feng et al., 
2000) 
Sez6-/- Sez6-tm1.1Sest Dr. Jenny Gunnersen (University of Melbourne) 
(Gunnersen et 
al., 2007) 
Sez6LoxP/LoxP  Dr. Jenny Gunnersen (University of Melbourne) 
(Gunnersen et 
al., 2007) 
Sez6-/-: 
GFP-M  In house (ZNP)  
Sez6LoxP/LoxP: 
SlickV  In house (ZNP)  
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2. Chemical compound and administration 
BACE1 inhibitor NB-360 was kindly provided by Dr. Ulf Neumann and Dr. Derya R. 
Shimshek (Novartis Institutes for BioMedical Research; Basel, Switzerland) (Neumann et 
al., 2015). The structural formula of NB-360 is showed in Figure 9. NB-360 was mixed in 
mice food in the final concentration of 250 mg/kg. 
 
Figure 9: Structural formula of NB-360 
Tamoxifen (Sigma-Aldrich) was used to induce single cell genetic modification in 
Sez6LoxP/LoxP:SlickV mice. Tamoxifen was dissolved in a mixture of ethanol and corn oil 
(1:10 ethanol: corn oil) at the final concentration of 20 mg/ml. The application of tamoxifen 
was performed by oral gavage. The tamoxifen was given to mice at 0.25 mg per body 
weight (Ochs et al., 2015). The structural formula of tamoxifen is showed in Figure 10. 
 
Figure 10: Structural formula of tamoxifen 
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3. Genotyping 
The Genotypes of all mice lines were determined by polymerase chain reaction (PCR). A 
small piece of tissue was obtained from each mouse. Invisorb® DNA Tissue HTS 96 Kit/C 
(Stratec molecular) was used for DNA extraction. In brief, 400 μl of Lysis Buffer G was 
incubated with mouse tissue overnight under 52°C shaking condition, follow by 1700g 
centrifugation for 10 mins. The supernatant was transferred into collection plate and mix 
with 200 μl binding buffer A, follow by 1700 g centrifugation for 5 mins. After discarded 
the filtrated, the pellet was washed in 550 μl washing buffer, followed by twice 5 mins 
centrifugation at 1700 g. Finally, 100 μl of warmed (52°C) elution buffer was used to 
collects the DNA extraction.  
The extracted DNA was used for PCR to identify the genotypes of each animal. The 
primers are listed in Table 5. The formulation of PCR solution is listed in Table 6. The 
PCR solution was placed in a thermocycler. The PCR program is listed in Table 7. PCR 
products were analyzed by gel electrophoresis. The samples were loaded to 1.5% 
agarose gel with SYBR® gold nucleic acid gel stain. The agarose gel was immerged into 
TAE running buffer. DNA migration was driven by 120-195 V electric fields for 60-90 
minutes. A photograph of the gel was taken under UV light source for documentation. 
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Table 5: Primers for Genotypes 
 Primer Sequence 
Bace1-/- 
Forward CGGGAA ATGGAA AGGCTACTCC 
Reverse TGGATGTGGAATGTGTGCGAG AGGCAGCTTTGTGGAGATGGTG 
APP-/- Forward GAGACGAGGACGCTCAGTCCTAGGG Reverse ATCACCTGGTTCTAATCAGAGGCCC 
SlickV Forward TCTGAGTGGCAAAGGACCTTAGG Reverse CGCTGAACTTGTGGCCGTTTACG 
GFP-M Forward TCTGAGTGGCAAAGGACCTTAG Reverse TGAACTTGTGGCCGTTTACG 
Sez6-/- Forward 
CGTATGGCATCTGTGACCTG 
GTAACCTTCGGGCTCCATCCTC 
Reverse GAACTTCCATTGCTAGGAAACAGAC 
Sez6LoxP/LoxP Forward 
CGTATGGCATCTGTGACCTG 
GTAACCTTCGGGCTCCATCCTC 
Reverse GAACTTCCATTGCTAGGAAACAGAC 
 
Table 6: PCR solution 
Items Volume 
Onetaq hotstart quickload 12.5 μl 
Forward primer 0.5 μl 
Reverse primer 0.5 μl 
Template DNA 0.5 μl 
Distilled water 10 μl 
 
Table 7: PCR program 
Step Temperature (°C) Time (s) 
1 94 180 
2 94 30 
3 60 60 
4 68 20 
5 68 120 
6 10 ∞ 
Step 2-4: repeat for 35 times. 
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4. Protein Extraction and Immunoblotting 
Mouse brains were harvested and separated to left and right cerebral hemispheres. Both 
hemispheres were snap freezing by liquid nitrogen and stored at -80°C. The membrane 
protein and soluble protein were extracted from brain tissues and separated using DEA 
buffer (50 mM NaCl, 0.2% diethylamine, pH = 10) and RIPA buffer (20 mM Tris-HCl, pH 
= 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 0.5% sodium deoxycholate, 
0.05% Triton X-100) with freshly supplemented protease inhibitors (P8340, Sigma-
Aldrich). Using the BCA method, concentrations of total protein were measured. 
Protein samples were mixed with Laemmli sample buffer supplemented with 2-
mercaptoethanol and separated by SDS-PAGE. The electrophoresis of SEZ6 were 
performed in Tris-glycine gels with Tris-buffer (25 mM Tris, 190 mM glycine) and 
transferred onto polyvinylidene difluoride membranes (Amersham Hybond P 0.45 PVDF, 
GE Healthcare Life Science). APP C-terminal fragment (APP-CTF) was separated using 
Tricine Protein Gels (10-20%, Novex, Thermo Fisher Scientific) in Tris-tricine buffer 
(Novex, Thermo Fisher Scientific), followed by transferred onto nitrocellulose membranes 
(GE Healthcare Life Science). Both nitrocellulose and PVDF membranes were incubated 
for 1 h at room temperature with I-Block solution (0.2% I-BlockTM Thermo Fisher 
Scientific, 0.1% Tween 20 in PBS). Followed by overnight incubation with primary 
antibodies respectively (anti-SEZ6 antibody was provided by Dr. Gunnersen; anti-sAPPβ 
antibody: 18957 IBL; anti-β-CTF antibody: Y188, Abcam; in diluted I-Block solution) at 
4°C. After 3 times washing by TBS-T buffer (140 mM NaCl, 2.68 mM KCl, 24.76 mM Tris, 
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0.3% Triton X-100, pH = 7.6), membranes were incubated with HRP-conjugated 
secondary antibody. Bound antibodies were visualized by using enhanced 
chemiluminescence (Thermo Fisher Scientific). Immunoblotting were performed on a 
LAS-4000 image reader and Multi-Gauge V 3.0 software were used for quantification 
analysis. 
5. Cranial window implantation 
Both genders were used in this experiment. At 2-month of age, the cranial window 
implantation surgery was performed. The surgery protocol was reported previously 
(Fuhrmann et al., 2007; Holtmaat et al., 2009). In brief, after anesthesia by intraperitoneal 
injection of the mixture of ketamine (130 mg/kg b.w. WDT/Bayer Health Care) and 
xylazine (10 mg/kg b.w. WDT/Bayer Health Care), mouse was fixed on the 
stereotaxic surgical setup (Figure 11A). Dexamethasone (6 mg/kg b.w. of Sigma) was 
applied by intraperitoneal injection to prevent development of cerebral edema. The mouse 
skull was exposed and cleaned by scalpel, then the piece of skull which was marked 
(Figure 11B). After carefully taking out the skull, the mice cerebral cortex was exposed 
(Figure 11C&D). A piece of coverslip was quickly fixed on top of cortex together with a 
metal bar by dental cement (Figure 11E). After surgery, the mice were put in a warm box 
for palinesthesia (Figure 11F). They received Carprofen (7.5 mg/kg b.w. Pfizer) and 
Cefotaxime (5 mg/kg b.w. Pharmore). The mice were singly housed for the 4-week 
recovery period with continuous postoperative observation. 
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Figure 11: mouse cranial window implantation surgery 
(A) A mouse was anesthetized and fixed on stereotaxic setup. (B) The skull was exposed, 
and a 4-mm diameter circle was marked. (C) A piece of the skull has been removed. (D) 
A 4-mm diameter cranial window. (E) The cranial window was covered by coverslip which 
is fixed to skull by dental cement. (F) After a few days of recovery, the mouse was healthy. 
C-D Scale bars: 1 mm. A, E & F Scale bars: 20 mm. (Kindly provide by Dr. Rodrigues) 
6. Two-Photon in vivo imaging 
Our main focused region is the layer V pyramidal neurons in the cerebral cortex. The 
apical dendrites of these neurons are labeled by eGFP and eYFP in GFP-M and SlickV 
mice respectively. Using LSM 7MP microscope (Carl Zeiss), we repeatedly imaged these 
apical dendrites. In general, mouse with cranial window was anaesthetized by isoflurane 
(1% in 95% O2, 5% CO2) and fixed under the microscope. Their body temperature was 
maintained by self-regulating heating pad (Fine Science Tools GmbH) and each image 
session was lasted less than 90 mins. All images were acquired through a water-
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immersion objective (20x, NA=1.0; Carl Zeiss) with 920 nm wavelength femtosecond 
laser which is generated from Mai Tai DeepSee laser generator (Spectra Physics). Two 
types of images were acquired from each animal: (1) overview images which is 424 × 424 
pixel per image frame (0.83 µm/pixel) with 3 μm axial resolution; (2) dendritic images 
which is 512 × 256 pixels per image frame (0.138 µm/pixel) with 1 μm axial resolution.  
 
Figure 12: Two-Photon imaging 
(A) A photograph of the mouse head with cranial window. The metal bar is used to fix the 
mouse under the 2P microscope. (B) Stereomicroscopic image of the brain surface. (C) 
Wide-field and (D) 2-photon micrograph of the apical dendrites of layer V pyramidal 
neurons in cortex of GFP-M mouse. (Kindly provide by Finn Peters) 
 
7. Immunohistochemistry and confocal imaging 
Mouse was deeply anesthetized by intraperitoneal injection of mixture of ketamine (130 
mg/kg b.w. WDT/Bayer Health Care) and xylazine (10 mg/kg b.w. WDT/Bayer Health 
Care). Then the animal was placed on the perfusion stage and exposed the peritoneal 
cavity. After exposure of hart, a 25-gauge needle, which is attached to a peristaltic pump 
via silicon tubing, was incised into the left ventricle. After turning on peristaltic pump at a 
rate of 7 ml/min, an incision on right atrium was quickly made to allow drainage. 15 ml of 
phosphate-buffered saline (PBS) followed by 10 ml of 4% formalin solution was used for 
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each animal. Then the mouse brains were dissected with post-fixation for 24 hours in 4% 
formalin. The fixed brains were sliced by vibratome (VT1000S, Leica) into 50 μm coronal 
sections. The immunohistochemistry protocol is list in Table 8. 
Table 8: immunohistochemistry protocol. 
Step Solution Company Time 
Permeabilization 1% Triton X-100 Sigma-Aldrich 2-hours 
Blocking 10% normal goat serum Sigma-Aldrich 2-hours 
Antibody 1:500 anti-GFP Alexa 488  Thermo Fisher 4-hours 
Washing PBS Sigma-Aldrich 5 × 10 min 
Mounting Fluorescence conserving media Dako  
 
8. Hippocampal slice preparation and electrophysiological recordings 
After treated with BACE1 inhibitor or EE, WT and Sez6-/- mice were anesthetized with 
isoflurane (1% in 95% O2, 5% CO2). Then they were euthanatized by cervical dislocation. 
Their brains were quickly harvest and transferred into ice-cold carbogenated (95% of O2 
and 5% of CO2) cutting solution (Table 9). Then 350 μm sagittal sections were performed 
to fresh obtained mouse brain by vibratome (VT1200S, Leica). The brain slices rest in 
35°C artificial cerebrospinal fluid (aCSF) (Table 9) for 30 mins and another 60 mins at 
room temperature (21 - 22°C). 
We tested field excitatory postsynaptic potentials (fEPSPs) in Schaffer collaterals-CA1 
synapse. The recording electrodes were homemade glass microelectrode (1-3 MΩ) 
produced by P-97 puller (Sutter Instrument). After filled with aCSF, the recording 
electrodes was placed in the CA1 stratum radiatum. Two platinum/iridium concentric 
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stimulation electrodes (PI2CEA3, Life Science) were placed at both side of recording 
electrodes (Figure 13). The field potentials were amplified 100× using an EXT-10C 
amplifier (National Instruments) and digitized with BNC-2090A (National Instruments).  
Table 9: Solutions for hippocampal slice preparation and electrophysiological 
recordings 
Chemical compound Cutting solution Artificial cerebrospinal fluid 
NaCl 125 mM 125 mM 
KCl 2.5 mM 2.5 mM 
NaH2PO4 1.25 mM 1.25 mM 
NaHCO3 25 mM 25 mM 
MgCl2 6 mM 1 mM 
CaCl2 0.5 mM 2 mM 
D-glucose 25 mM 25 mM 
 
 
 
Figure 13: Schematic drawing of mouse hippocampal slices 
Schaffer collaterals-CA1 pathway is axons projection from CA3 to CA1. The stimulation 
is performed in an antegrade or retrograde manner by two stimulation electrodes that 
were positioned in the stratum radiatum. CA1: Cornu Ammonis 1; CA3: Cornu Ammonis 
3. (Kratzer et al., 2012). 
For paired pulse facilitation (PPF), two stimulations with interval 50, 75, 100, 150, 200, 
400, 800 and 1200ms were given to hippocampus slices. For Input-output curves, the 
stimulation intensity was increased stepwise from 0 v to 30 v. For the long-term 
potentiation (LTP), the stimulation intensities were adjusted to 50% of maximum 
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amplitude, and the stimulation frequency of each stimulation electrodes was set to every 
15 s (0.033 Hz). Once reaching stable stimulation-response states, the Schaffer-
collaterals were tetanized by 1 second of high frequency stimulation (HFS, 100Hz). Follow 
by 60 mins continuously recordings. Data were analyzed using the WinLTP 2.10 program. 
9. Environmental enrichment  
Environmental enrichment (EE) housing condition is a group (3-6) of mice in 48cm × 48cm 
× 48cm cage with 2 running wheels, one ladder, one tunnel and multiple hanging toys 
which were changed or reposition 3 times per week (Figure 14). Same gender mice from 
same litter were placed into EE housing conditions from 2-month-old or 3-month-old for 
6-7 weeks. Both genders of animals were use in this experiment. The aggressive mice 
were removed from EE housing. Standard cages were 30 × 15 × 20 cm without wheels 
or toys. 
 
Figure 14: Environmental enrichment housing condition 
Photograph of Environmental enrichment housing condition (left) and standard housing 
(right) (Zou et al., 2016). 
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10. Images, data processing and statistics  
Dendritic spines were counted manually. For confocal micrographs, CA1 were counted in 
z-stacks by manually scrolling through the images. Because the z-plane resolution was 
low in two-photon micrographs, the dendritic spines of cortical neurons were restricted to 
laterally protruding spines. The dendritic spines dynamic analysis protocol was described 
before (Holtmaat et al., 2009). In brief, dendritic spines without changing location between 
consecutive imaging sessions (acceptable range < 1 µm) were defined as persistent 
spines. Newly emerged spines were defined as gained spine. Spines which were 
disappeared were defined as lost spines. For GFP-M mice, 8-10 dendrites were analyzed 
per mouse; for SlickV mice, 2-6 dendrites were analyzed per mouse.  
GraphPad Prism (GraphPad Software, USA) was used for Statistical analyses. Data were 
presented as mean ± SEM. Statistical significances were determined by comparing 
means of different groups using two-tailed Student’s t-text, one-way or two-way ANOVA, 
as specified in the figure legends. Bonferroni post-hoc tests were used to compare the 
different groups. 
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RESULTS  
Part 1  
SEZ6 and dendritic spine plasticity  
1. SEZ6 and dendritic plasticity under basal condition 
1.1. SEZ6 regulates dendritic spine density and morphology 
To study the function of SEZ6 on dendritic spine density and plasticity, we first analyzed 
the dendritic spine densities of adult Sez6-/-:GFP-M and Sez6+/-:GFP-M mice. 
Sez6+/+:GFP-M mice were served as control. We imaged layer I dendritic tufts of cortical 
layer V pyramidal neurons in these mice using in vivo two-photon microscopy. In line with 
previses report, the dendritic spine densities of Sez6-/- mice were reduced (Figure 15A) 
(Gunnersen et al., 2007). Furthermore, we demonstrated that SEZ6 was involved in 
dendritic spine density reduction in a dose dependent manner (Figure 15A). 
Then, we classified all the spines into 3 categories (e.g. stubby, thin and mushroom 
spines) based on their morphology (Harris and Kater, 1994; Harris et al., 1992). We also 
calculated the number of dendritic filopodia (Figure 15B). Dendritic filopodia are hair-like 
transient structures which do not have bulbous head as dendritic spines. These structures 
may receive synaptic input. The newly formed spine is likely developed along the filopodia 
(Fiala et al., 1998; Hayashi and Majewska, 2005). As shown in Figure 15B, all of 3 types 
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of spines are significantly reduced in Sez6-/-:GFP-M mice. The densities of filopodia were 
normal in both Sez6-/-:GFP-M and Sez6+/-:GFP-M mice, suggesting the formation rate of 
new gain spine may not affected (Figure 15B). 
 
 
Figure 15: Dendritic spine density and morphology is altered in Sez6-/- mice 
(A) Lack of SEZ6 alters dendritic spine density in apical dendrites of layer V pyramidal 
neurons in a dose depended manner. (B) Quantification of dendritic spine sub-type shows 
that stubby, thin and mushroom spines are reduced in Sez6-/- mice. The density of 
dendritic filopodia is normal. Animals per group: n=5. Two-tail Student’s t-test, p<0.05 (*). 
Error bars represent S.E.M. 
 
1.2. Knockout of Sez6 in adult mice decreases dendritic spine density 
The expression level of SEZ6 is high during early development, indicating it has important 
function for neuronal development. To exclude developmental deficits, as well as further 
study the impact of lack of SEZ6 in mature neurons, we used the conditional Sez6 
knockout mice, Sez6LoxP/LoxP:SlickV mice. In Sez6LoxP/LoxP mice, Sez6 exon 1 was inserted 
-46-	
 
with two flanked LoxP sequences (Figure 16A) (Gunnersen et al., 2007), which can be 
cleaved by activated Cre DNA-recombinase. SlickV mice express a modified Cre 
recombinase, CreERT2, in a small subset of enhanced yellow fluorescent protein (eYFP) 
positive neurons in cortex and hippocampus (Figure 16A,B) (Young et al., 2008). CreERT2 
is a ligand-dependent Cre recombinases which is only activated (nuclear translocated) by 
administration of tamoxifen to the animal (Feil et al., 2009; Ochs et al., 2015). Any 
alteration on eYFP and CreER(T2) positive neurons are mainly due to the cell 
autonomous knockout of Sez6. This cell specific gene editing occurs only in a small 
subset of neurons, the majority of neighboring eYFP and CreER(T2) negative neurons 
are not affected by tamoxifen treatment (Feil et al., 2009; Ochs et al., 2015; Young et al., 
2008). 
 
 
Figure 16: Sez6LoxP/LoxP:SlickV mice 
(A) Schematic diagram of tamoxifen activated CreER(T2) gene recombinases induced 
Sez6 knockout in Sez6LoxP/LoxP:SlickV mice. (B) Enhanced yellow fluorescent protein 
(eYFP) expression pattern in Sez6LoxP/LoxP:SliceV mice. 
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By applying tamoxifen to Sez6LoxP/LoxP:SlickV mice, we generated Sez6cKO/cKO:SlickV 
mice. We performed in vivo two-photon microscopy to layer I dendritic tufts of cerebral 
cortex layer V pyramidal neurons in adult Sez6cKO/cKO:SlickV mice (Figure 17A). As shown 
in Figure 17B, the dendritic spine densities of cortical layer V neurons are significantly 
reduced (Figure 17B). Then we investigated apical and basal dendrites of hippocampal 
CA1 eYFP and CreERT2 positive neurons after tamoxifen application using confocal 
microscopy (Figure 17C). Compared to vehicle control, the spine densities of both apical 
and basal dendrites showed a notable reduction in Sez6cKO/cKO:SlickV mice (Figure 17D). 
As mention before, alteration in the extracellular environment is unlikely because the gene 
editing occurs only in a very small neuronal population. Therefore, we concluded that lack 
of SEZ6 induced dendritic spine deficits in a cell autonomous manner. 
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Figure 17: Knockout of Sez6 impairs dendritic spine density in adult mice 
(A) The apical dendrites from layer V cortical neurons were labeled by enhanced yellow 
fluorescent protein (eYFP). Micrographs of dendrites are acquired by sequential imaging 
by in vivo two-photon microscopy. Tamoxifen (0.25 mg/g b.w. in a mixture of 1:10 ethanol: 
corn oil) or vehicle treatment started at day 8 and continued for 5 days (highlighted in 
pink). Scale bar: 10μm. (B) Knockout of Sez6 impairs dendritic spine density in mature 
layer V cortical neurons. Top: absolute values; two-way ANOVA F(4,40)=4.21, interaction 
p<0.01, Genotype p<0.001, Days p<0.001. Bottom: The absolute values were normalized 
to the average of the first two timepoints. Two-way ANOVA F(4,40)= 4.69, interaction 
p<0.01, Genotype p<0.01, Days p=0.11. Tam: tamoxifen; Veh: vehicle. Animals per 
group: n=6. p<0.01(**). Error bars represent S.E.M. (C) The apical and basal dendrites of 
CA1 pyramidal neurons from Sez6-cKO mice and control were imaged by confocal 
microscopy. Scale bar: 5μm. (D) the dendritic spine density is reduced in Sez6-cKO CA1 
neurons. Animals per group: n=3. Two-tail Student’s t-test, p<0.05(*). Error bars represent 
S.E.M. 
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1.3. Sez6-/- mice have normal spine plasticity under base line condition 
Dendritic spine plasticity is another important physiological feature. Therefore, it is 
reasonable to speculate that the dendritic spine plasticity might also regulated by SEZ6. 
To test this hypothesis, we repeatedly imaged Sez6-/-:GFP-M and Sez6+/-:GFP-M mice 
every 7 days over 4 weeks using in vivo two-photon microscopy. Then we analyzed the 
total dendritic spine density (Figure 18A), the fractions of new gained spines (Figure 18B) 
and lost spines (Figure 18C), as well as the spine turn-over rate (TOR) (Figure 18D). To 
our surprise, the fractions of new gained spines and lost spines, as well as spine TOR did 
not show obvious difference in both Sez6+/-:GFP-M and Sez6-/-:GFP-M mice compare 
with WT controls (Figure 18B-D). These results demonstrated that SEZ6 has important 
function in regulating dendritic spine density, but the spine plasticity remains unaffected. 
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Figure 18: Dendritic spine plasticity is normal in Sez6-/- mice 
(A) Quantitative analysis of the dendritic spine density over time in Sez6-/-:GFP-M, Sez6+/-
:GFP-M and Sez6+/+:GFP-M mice. Two-way ANOVA F(4,12)=0.32, interaction p=0.92, 
Genotype p=0.12, Days p<0.01; (B) Quantitative analysis of the new gained spines. Two-
way ANOVA F(4,12)=0.97, interaction p=0.46, Genotype p=0.97, Days p=0.16; (C) 
Quantitative analysis of the lost spines. Two-way ANOVA F(4,12)=0.63, interaction 
p=0.65, Genotype p=0.83, Days p=0.34. (D) Quantitative analysis of the spines turn-over 
rate (TOR). Two-way ANOVA F(4,12)=0.68, interaction p=0.62, Genotype p=0.91, Days 
p=0.07. Error bars represent S.E.M. 
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1.4. Sez6 knockout mice have impaired synaptic plasticity 
Next, we investigated the role of SEZ6 in functional synaptic plasticity in hippocampal 
Schaffer collaterals-CA1 pathway by analysing PPF (paired-pulse facilitation), stimulus-
response relationship and LTP (long-term potentiation) (Figure 19).  
In the PPF test, we used stimulation intervals from 35 ms to 1200 ms. The results showed 
that Sez6-/- brain slices only have a minor elevation at 35 ms stimulation interval. For the 
longer intervals, Sez6-/- brain slices do not have differences compared to WT controls, 
suggesting SEZ6 is not involved into pre-synaptic plasticity (Figure 19A).  
Then, we investigated the stimulus-response relationship by gradually increased 
stimulation intensity. Sez6-/- brain slices showed a significant reduction in synaptic 
transmission (Figure 19B).  
Finally, we performed LTP measurement. After 10 minutes of baseline recordings, the 
Schaffer collaterals were tetanized by high-frequency stimulation (HFS; 100 pulses/s), 
followed by a continuous recording for 50 minutes. HFS caused a pronounced post-
tetanic potentiation in WT mice, but the magnitude of LTP in Sez6-/- brain slices were 
significantly reduced (Figure 19C, D). Our findings suggest that SEZ6 regulates synaptic 
transmission and LTP mainly in the post-synaptic compartments. 
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Figure 19: SEZ6 regulates synaptic plasticity 
SEZ6 is involved in synaptic function. (A) The Paired-pulse ratio in hippocampal slices of 
Sez6-/- brain slices have no different compare to WT control. Two-way ANOVA 
F(8,104)=1.46, interaction p=0.18, Genotype p=0.20, Days p<0.001. (B) Sez6-/- mice 
have a significant reduction in stimulus-response relationship test. Two-way ANOVA 
F(6,114)=11.02, interaction p<0.001, Genotype p<0.001, Days p<0.01. Bonferroni post-
test p<0.05 (*); p<0.01(**). (C) Representative traces of evoked field excitatory 
postsynaptic potential (fEPSP) acquired from Sez6-/- brain slices. LTP was induced by 
high-frequency stimulation (HFS) at Schaffer collaterals. Sez6-/- brain slices presented a 
notable impairment in LTP. (D) Summary graph of LTP magnitudes calculated 40 to 50 
minutes after HFS from graphs in panels (C). Two-tail Student’s t-test, p<0.05(*). Animals 
per group: n=7-9. Error bars represent S.E.M.  
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2. Adaptive plasticity of dendritic spine is impaired in Sez6-/- mice 
2.1. Environmental enrichment does not alter spine plasticity in Sez6-/- mice 
Environmental enrichment (EE) is a combination of enriched social interactions and 
housing conditions, including enhanced opportunities for cognitive, sensory, and motor 
stimulation. EE provides a larger number of learning opportunities than standard housing 
conditions (Leuner and Gould, 2010; van Praag et al., 2000). Increased environmental 
complexity has been shown to have a beneficial effect on many aspects of brain structure, 
including increased neurogenesis, synaptogenesis and a strongly increase in dendritic 
spine dynamics (Barnea and Nottebohm, 1994; Globus et al., 1973; Jung and Herms, 
2014). Although spine density is reduced in Sez6-/- mice, the spine dynamics is normal 
under base line condition. Interestingly SEZ6 is upregulated under EE condition (Rampon 
et al., 2000), suggesting SEZ6 may be involved in adaptive synaptic alterations within the 
adult mouse brain. To investigate whether lack of SEZ6 has a functional consequence in 
neural circuit remodeling in the adult brain, we applied EE stimulation to Sez6-/-:GFP-M 
mice. WT (Sez6+/+:GFP-M) mice served as control. After two imaging timepoint, both 
Sez6-/-:GFP-M and WT mice were exposed to EE over 6 weeks. The spine densities and 
dynamics were continuity monitored using in vivo two-photon microscopy. 
In agreement with earlier reports (Jung and Herms, 2014; Zou et al., 2016) a steady 
increased of both mean and normalized spine densities were seen in WT mice under EE 
condition (Figure 20A&B filled circles). In sharp contrast, both mean and normalized spine 
densities were not altered by EE in Sez6-/-:GFP-M mice (Figure 20A&B open circles). This 
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increased spine density in WT mice is mainly due to an enhanced fraction of new gained 
spines and stable spines (Figure 20C&D filled circles). There is a notable increase in new 
gained spine in WT mice at first timepoint after EE, which remains unaffected in Sez6-/-
:GFP-M mice (Figure 20C). The number of lost spines is not altered in both knockout and 
WT mice (Figure 20E). The survival of pre-existing spine is a bit lower in Sez6-/-:GFP-M 
mice compare to WT control, but it does not reach to statistical significant (Figure 20F). 
Collectively, these data demonstrate an essential role of SEZ6 in regulating adaptive 
remodeling in the adult mice brain.  
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Figure 20: Dendritic spines adaptive plasticity is impaired in Sez6-/- mice 
Adaptive plasticity of dendritic spines is impaired in Sez6-/- mice. Weekly imaging of GFP-
labeled apical dendrites of layer V pyramidal neurons was performed since day 0. 
Enriched environment (EE) stimulation stars from day 8. Quantifications of mean (A) Two-
way ANOVA F(7,49)=5.58, interaction p<0.001) and relative (B) F(7,49)=4.10, interaction 
p<0.01) spine density, fraction of new gained spine (C) Two-tail Student’s t-test, WT d7 
Vs. d14, p=0.05 (#); Sez6-/- d7 Vs. d14 p=0.48), stable spine (D; ANOVA F(6,42)=2.07, 
interaction p=0.07), lost spines (E) F(6,42)=2.44, interaction p<0.05) and survival of pre-
existing spine (F). Bonferroni post-test p<0.05 (*); p<0.01(**). Error bars represent S.E.M. 
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2.2. Hippocampal synaptic plasticity is not affected by environmental enrichment 
in Sez6-/- mice 
We have shown that the activity-induced structural spine plasticity is disturbed in Sez6-/- 
mice. To further examine if damaged spine plasticity on dendrites has functional 
consequences, we housed Sez6-/- mice and their WT littermates under EE condition over 
6 weeks and monitored the LTP on hippocampal Schaffer collaterals-CA1 pathway. EE 
enhanced hippocampal-CA1 LTP in WT control mice (Cui et al., 2006; Huang et al., 2007; 
Kempermann et al., 1997; van Praag et al., 2000). But LTP did not increase due to 
enriched environment in Sez6-/- mice.  
 
Figure 21: SEZ6 is a key factor underlineing environmental enrichment induced 
LTP increase 
(A) Prolonged exposure to an enriched environment (EE) enhances hippocampal LTP in 
WT mice. (B) Quantifications of (A). (C) Prolonged exposure to an EE does not alter 
hippocampal LTP in Sez6-/- mice. (D) Quantifications of (C). Two-tail Student’s t-test, 
p<0.05 (*). Error bars represent S.E.M. 
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Part 2  
BACE1 Inhibition Impairs Synaptic Plasticity via SZE6 
1. NB-360 strongly suppresses proteolytic activity of BACE1 
NB-360 is a novel 3rd generation BACE1 inhibitor developed by Novartis Pharma AG 
(Basel, Switzerland). NB-360 has small molecule weight, and does cross the blood-brain-
barrier efficiently (the molecular structure is illustrated at Figure 9) (Neumann et al., 2015). 
In this study, NB-360 was mixed in the mouse food pellets. The advantage of this 
approach is minimizing the stress to experimental animals caused by repeated drug 
administration. It might also reach to a more stable inhibitory effect because mice 
consistently consume these food pellets. By monitoring the weight of the food, we 
calculated that each mouse consumed 4.6 ± 0.1 g food pellets per day (N = 44) in average 
which is corresponding to a daily oral dose of 20 μM/kg/day. The body weight and health 
conditions are monitored on daily basis. During and after NB-360 treatment, we did not 
observe any impairment, expect hair depigmentation alteration (Figure 22). It is due to 
that NB-360 inhibits BACE2 which has been reported important for melanogenesis (Filser 
et al., 2015; Neumann et al., 2015; Rochin et al., 2013; Shimshek et al., 2016).  
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Figure 22: Chronic treatment of NB-360 induces hair depigmentation in mice 
Mice was treated with NB-360 (right) or vehicle (left) for 21 days. NB-360 caused hair 
depigmentation in mice. 
 
We first verified the inhibitory effect of NB-360. After administration of NB-360 or vehicle 
over 3 weeks, the mice cerebrums were harvested. The samples were homogenized and 
separated to soluble fractions and membrane extracts for immunoblotting. We analysed 
the protein levels of known BACE1 substrates: flSez6 (full length Sez6) and its cleavage 
product sSez6 (soluble Sez6), as well as the cleavage product of APP, sAPPβ (soluble 
APP beta) and β-CTF (C-terminal fragment of APP) (Kuhn et al., 2012; Pigoni et al., 
2016). Samples from Bace1-/- (Bace1 knockout) mice served as positive controls. 
Samples from APP-/- (APP knockout) mice were used for verifying the specificity of sAPPβ 
and β-CTF antibodies (Figure 23). The signal intensity of each immunoblot was analysed 
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using the Multi-Gauge software and normalized to the value of control (C57BL/6 vehicle) 
group. The results showed that after NB-360 treatment flSez6 was significantly increased, 
whereas the cleavage products sSez6, sAPPβ and β-CTF were significantly decreased. 
Bace1-/- vehicle condition showed similar results. In summary, we confirmed that NB-360 
is a potent BACE1 inhibitor.  
 
Figure 23: NB360 strongly inhibits BACE1 proteolytic activity 
C57BL/6J mice were applied with food pellets which contains 0.25g/kg of NB-360 or 
vehicle for 21 days. Bace1-/- and APP-/- mice were applied vehicle food pellets 21 days. 
Mice whole brain homogenates were separated to soluble fractions and membrane 
extracts for immunoblotting. Actin and Calnexin were used as loading controls. Animals 
per group: n=4. (A) Both membrane extracts and soluble fractions were probed by anti-
Sez6 antibody. Base on different fractions, full length membrane attached SEZ6 and 
soluble SEZ6 were separated. (B) Quantitative analysis of the signal intensity of full length 
and soluble SEZ6. One-way ANOVA, full length Sez6: F(2,9)=15.70 p<0.01, soluble 
Sez6: F(2,9)=67.86 p<0.001. Both membrane extracts and soluble fractions were probed 
by anti-sAPPβ (18957, IBL) and anti-β-CTF (Y188, Abcam) antibodies. APP-/- mice was 
used to antibody validation. (D) Quantitative analysis of the signal intensity of sAPPβ and 
β-CTF. One-way ANOVA, sAPPβ: F(2,9)=44,62 p<0.001, APP β-CTF: F(2,9)=44.05 
p<0.001. Bonferroni’s test was used for post-hoc analysis. p<0.05(*), p<0.001(***). Error 
bars represent S.E.M. 
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2. BACE1 inhibition affects dendritic spine plasticity via SEZ6  
2.1. Effect of BACE1 inhibition in Sez6-/- mice 
Previously, Filser and colleagues demonstrated that strong BACE1 inhibition by two 
structurally different inhibitors, SCH1682496 (Merck & Co) and LY2811376 (Eli Lilly and 
Company), impairs dendritic spine plasticity (Filser et al., 2015). Here, we verified whether 
NB-360 has similar impacts on spine plasticity. Using chronic in vivo two-photon 
microscopy, we imaged layer I dendritic tufts of cortical layer V pyramidal neurons in 
inhibitor treated WT control (Sez6+/+:GFP-M) mice (Figure 24A upper line). The mice were 
repeatedly imaged every 7 days. The first two timepoints were considered as baseline 
recordings, and then NB-360 was applied to mice from day 8 till day 28 (3 weeks) as 
highlighted in grey (Figure 24). We also recorded three more timepoints as post treatment 
recovery period. In line with previous data, NB-360 administration reduced total spine 
density in control mice (Figure 24B, upper filled circles). Then we set the total dendritic 
spine density of two pre-treatment time-points as 100% for each animal, and normalized 
the rest of timepoints in ordered to emphasize the effects of inhibitor treatment (Figure 
24B, lower). Our data also showed that NB-360 reduced the density of the persistent 
spines (present for ≥ 7 days), as well as newly gained spines in control mice (Figure 24C-
D). Shortly after withdrawing NB-360, the deficits were gradually recovered. Since all 
three different BACE1 inhibitors (SCH1682496, LY2811376 and NB-360) impair spine 
density, it is likely an on-target side effect.  
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As a protease, BACE1 most likely regulates dendritic spine plasticity via it substrates. 
Sez6-/- mice showed similar deficit as BACE1 inhibitor-treated mice, like reduced dendritic 
spine density and spatial memory deficit. Therefore, we hypothesized that BACE1-
inhibition influences spine dynamic may via SEZ6 protein. To investigate this hypothesis, 
we applied NB-360 to Sez6-/-:GFP-M mice and traced the spine density and dynamic as 
described in control mice (Figure 24A lower line). During base line condition, the dendritic 
spine density in Sez6-/-:GFP-M mice were 15.9 ± 9.4% lower compared to control mice. 
In contrast to control mice, NB-360 did not affect total spine density in Sez6-/-:GFP-M mice 
(Figure 24B, open circles). It is noteworthy that, NB-360 administration decreased the 
total dendritic spine density by 15.6 ± 8.9% in control mice, reaching a similar density as 
in Sez6-/-:GFP-M mice (Figure 24B). The spine dynamic was also analyzed in Sez6-/-
:GFP-M mice. The results showed that the structural plasticity is not affected by BACE1 
inhibitor treatment (Figure 24C-E). In summary, NB-360 alters spine density and plasticity 
in control mice but not in Sez6-/-:GFP-M mice, suggesting BACE1 mediated shedding of 
SEZ6 plays an important role in maintaining dendritic spine density under physiological 
conditions.  
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Figure 24: NB-360 alters dendritic spine plasticity via SEZ6 
(A) Images of apical dendrites of layer 5 neurons in layer 1 cerebral cortex. These apical 
dendrites were labelled by eGFP. The same dendrites were imaged every 7 days using 
in vivo 2-photon microscopy. BACE1 inhibitor (NB-360) treatment was applied from day 
8 till day 29. The treatment period is highlighted in gray. Vehicle was given to mice before 
and after NB-360 treatment period. Persistent spines (present ≥ 7 days): white 
arrowheads. Gained spines: green arrowheads. Lost spines: red arrowheads. Scale bar: 
10μm. (B-E) Quantitative analysis of the denticity of total spine (B), persistent spines (C), 
gained spines (D) lost spines (E) from Sez6+/+:GFP-M and Sez6-/-:GFP-M mice. (B Top) 
Absolut value, Two-way ANOVA F(7,77)=15.16, interaction p<0.001. (B Bottom) The 
normalized value relative to the average of the first two times points. Two-way ANOVA 
F(7,77)=12.28, interaction p<0.001. (C) Two-way ANOVA F(6,66)=13.75, interaction 
p<0.001. (D) Two-way ANOVA F(6,66)=4.75, interaction p<0.001. (E) Two-way ANOVA 
F(6,66)=6.74, interaction p<0.001. Animals per group: n=6-7. p<0.001(***). Error bars 
represent S.E.M.  
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2.2. Effect of BACE1 inhibition in Sez6cKO/cKO mice 
We have demonstrated that knockout Sez6 at adult stage impairs dendritic spine density. 
The protein levels of both BACE1 and SEZ6 are highest during early postnatal period in 
mice (Kim et al., 2002; Osaki et al., 2011; Willem et al., 2006). This indicates that they 
have important function for neuronal development. Then we wonder whether NB-360 
does not influence dendritic spine density and plasticity in Sez6-/- mice is due to 
developmental deficit or compensate effect occurred during development stage. To 
investigate this hypothesis, we again employed the Sez6cKO/cKO:SlickV mice. In this 
experiment, Tamoxifen was applied to 3-month-old mice for 5 consecutive days. Then, 9 
days was given to mice for recovery (as highlighted in purple) (Figure 25). Same method 
was performed to Sez6cKO/cKO:SlickV mice which is repeatedly imaging the layer I dendritic 
tufts of cortical layer V pyramidal neurons (Figure 25A). Sez6LoxP/LoxP:SlickV mice, which 
is without Tamoxifen treatment, served as control. After baseline recordings, NB-360 was 
applied to mice from day 8 till day 28 (3 weeks) as highlighted in grey (Figure 25), follow 
by recording of post treatment recovery period.  
Similar to GFP-M mice, BACE1 inhibitor administration impaired total spine density in 
control (Sez6LoxP/LoxP:SlickV) mice (Figure 25B, upper, filled circles). Then we set the total 
dendritic spine density of two pre-treatment time-points as 100% for each mouse, and 
normalized the rest of timepoints in order to emphasize the effects of inhibitor treatment 
(Figure 25B, lower, filled circles). NB-360 also affected spine dynamic, like reducing the 
density of the persistent spines (present for ≥ 7 days) (Figure 25C filled circles) and newly 
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gained spines (Figure 25D), as well as increasing lost spines (Figure 25E filled circles). 
Shortly after withdrawal NB-360, the deficits were gradually recovered. Similar as Sez6-/- 
mice, BACE1 inhibition did not alter total spine density and spine dynamic (fraction of 
persistent, new gained and lost spines) in Sez6cKO neurons (Figure 25B-E, open circles). 
Since SlickV mice have a very sparse and weak eYFP labeling, the total number of 
analyzed dendrites is lower compared to GFP-M mice (2-6 vs 8-10, respectively), 
resulting a high statistical variation. Therefore, a trend of reduced fraction of new gained 
spines did not reach statistical significance (p=0.19). Nevertheless, NB-360 treatment 
impairs the impaired total spine density and dynamic in both control mice (Sez6+/+:GFP-
M and Sez6LoxP/LoxP:SlickV). NB-360 treatment does not alter spine density and dynamic 
in both constitutive and conditional Sez6 knockout mice (Sez6-/-:GFP-M and 
Sez6cKO/cKO:SlickV). These data further support the hypothesis that SEZ6 mediates 
BACE1-inhibition-induced spine alterations. 
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Figure 25: NB-360 does not alter dendritic spine plasticity in Sez6cKO/cKO neurons 
(A) Images of apical dendrites of layer 5 neurons in layer 1 cerebral cortex. These apical 
dendrites were labeled by eYFP. The same dendrites were imaged every 7 days using in 
vivo 2-photon microscopy. Tamoxifen was applied to Sez6LoxP/LoxP:SlickV and 
Sez6cKO/cKO:SlickV mice from day -12 till day -8. Tamoxifen treatment period is highlighted 
in purple. BACE1 inhibitor (NB-360) treatment was applied from day 8 till day 29. NB-360 
treatment period is highlighted in gray. Vehicle was given to mice before and after NB-
360 treatment period. Persistent spines (present ≥ 7 days): white arrowheads. Gained 
spines: green arrowheads. Lost spines: red arrowheads. Scale bar: 10μm. (B-E) 
Quantitative analysis of the denticity of total spine (B), persistent spines (C), gained 
spines (D) lost spines (E) from Sez6LoxP/LoxP:SlickV and Sez6cKO/cKO:SlickV mice. (B Top) 
Absolut value, Two-way ANOVA F(7,70)=3.58, interaction p<0.01. (B Bottom) The 
normalized value relative to the average of the first two times points. Two-way ANOVA 
F(7,63)=4.16, interaction p<0.01. (C) Two-way ANOVA F(6,60)=2.71, interaction p<0.05. 
(D) Two-way ANOVA F(6,60)=1.52, interaction p=0.19. (E) Two-way ANOVA 
F(6,60)=2.73, interaction p<0.05. Animals per group: n=6. p<0.05(*), p<0.01(**). Error 
bars represent S.E.M.  
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3. Chronic application of NB-360 does not alter synaptic plasticity Sez6-/- mice 
Structural alterations of synapses are usually considered as an indicator for functional 
changes. We have demonstrated that NB-360 interferes spine plasticity via SEZ6. To 
investigate whether NB-360 impairs synaptic plasticity and whether it involves SEZ6 too, 
the WT mice (C57BL/6J) and Sez6-/- mice were applied with NB-360 or vehicle for 3 
weeks. At the last day of treatment, the mice were sacrificed, their brains were harvest 
and acutely sliced in 350 µm thick hippocampal slices for field recordings. The synaptic 
plasticity was test in hippocampus Schaffer collateral - CA1 pathway. After 20 min of 
baseline recordings, high frequency stimulation (HFS; 100 pulses/s) was used to induce 
hippocampal long-term potentiation (LTP) in Sez6-/- mice and WT mice, followed by 60 
min of continuous recording (Figure 26 A-B). HFS caused a notable post-tetanic 
potentiation in vehicle-treated WT mice. We also showed that NB-360 impairs LTP in WT 
mice (Figure 26C). Although the LTP is low in the CA1 synapse of Sez6-/- mice, NB-360 
treatment did not alter LTP (Figure 26C). Our results suggest that BACE1 inhibition 
induces synaptic plasticity deficits might involve SEZ6.  
Additionally, we investigated whether NB-360 induced LTP impairment is due to pre-
synaptic mechanisms. The pre-synaptic terminal is relatively normal in Sez6-/- mice, 
however BACE1 is enriched in pre-synaptic terminals. If NB-360 would induce pre-
synaptic alteration, it might be evidence which against SEZ6 involve in BACE1 inhibition 
induces synaptic plasticity deficits. To test this hypothesis, we monitored paired-pulse 
facilitation (PPF) at Schaffer collateral - CA1 synapses using two different inter-stimulus 
-67-	
 
intervals (ISIs), 35 ms and 50 ms. The results show that NB-360 treatment did not affect 
PPF in either WT or Sez6-/- mice (Figure 26D). Our findings showed that there is no 
obvious pre-synaptic alteration, implying that the LTP changes are most likely due to post-
synaptic alterations.  
 
Figure 26: NB-360 does not alter LTP in Sez6-/- mice 
(A) the LTP in WT brain slices was impaired by chronic treatment of NB-360. (B) Same 
treatment does influence LTP in Sez6-/- brain slices. Representative traces of evoked is 
shown respectively. Schaffer collaterals-CA1 pathway was tetanized using high-
frequency stimulation (HFS). red lines: fEPSP before stimulation; black lines: fEPSP after 
stimulation. (C) Quantitative analysis of the LTP magnitudes which is averaged from 50 - 
60 min. Two-way ANOVA F(1,24)=9.57, interaction p<0.01. Bonferroni’s post hoc test: 
p<0.01**, p<0.001***). Animals per group: n=7. (D) The paired-pulse facilitation was 
analyzed using 2 different intervals (35ms and 50ms) in NB-360 or vehicle treated WT 
and Sez6-/- mice. 35 ms: Two-way ANOVA F(1,23)=3.753, interaction p=0.07. 50 ms: 
Two-way ANOVA F(1,23)=1.917, interaction p=0.18. Animals per group: n=5-8. Error 
bars represent S.E.M. 
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DISCUSSION 
1. SEZ6 regulates dendritic spine density and plasticity 
Previous studies show that SEZ6 involves in many neuronal activities, including 
regulation of neurite development, dendritic spine density (Gunnersen et al., 2007). SEZ6 
is also proposed to be involved in the etiology of several neurodevelopmental disorders 
(Ambalavanan et al., 2016; Gilissen et al., 2014; Mulley et al., 2011; Yu et al., 2007). Here 
we confirmed that the dendritic spine density is decreased in conventional Sez6 knockout 
(Sez6-/-) mice. Then we show that SEZ6 regulates spine density in a dose depend 
manner, it means that the expression level is critical for the function of SEZ6. It also 
indicates that the proteinase (BACE1) which regulating the cell surface level of SEZ6, 
might influence spine density or dynamic via SEZ6 (Munro et al., 2016; Pigoni et al., 
2016). 
Sez6-/- mice show alterations in neurite branching during the development. Moreover, 
Sez6 knockdown in neurons caused altered calcium activity (Anderson et al., 2012; 
Gunnersen et al., 2007). The SEZ6 expression level is high during early postnatal stage 
(Kim et al., 2002; Osaki et al., 2011). To rule out developmental deficits, we used 
conditional knockout (Sez6cKO/cKO) mice, in which Sez6 gene deletion occurred only in the 
small subset of eYFP/CreERT2 positive neurons in adulthood. In these neurons, dendritic 
spine density is reduced similar to the situation in constitutive Sez6-/- neurons, indicating 
that SEZ6 is not only critical for neuronal development but also important for maintaining 
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the normal dendritic spine density in adult mice. In Sez6cKO/cKO mice, the spine density 
reduction in cortical neuron was smaller than that seen in Sez6-/- mice, which may be 
attributed to a general increase of the dendritic spine stability in adulthood (Grutzendler 
et al., 2002; Zuo et al., 2005). Using Sez6cKO/cKO mice, we can further pinpoint which SEZ6 
proteolytic fragments are involved. As mention before, SEZ6 is cut by BACE1, and the 
sSEZ6 is secreted to extracellular matrix. In Sez6cKO/cKO mice, the small subset eYFP 
positive Sez6cKO neurons lack cell-autonomous Sez6. These neurons were exposed to a 
relatively normal extracellular environment, since the proportion of Sez6cKO neurons is 
really low (Young et al., 2008). The soluble Sez6 levels is normal in the surrounding 
neuropil. In this context, the sSEZ6 is not actively involved in dendritic spine density 
regulation. Since the SEZ6-CTF will be further processed by γ-secretase (Pigoni et al., 
2016), it is not yet clear whether flSEZ6 or SEZ6-ICD is the critical player of regulating 
dendritic spine density. 
We classified the dendritic protrusions base on their morphology (Figure 27) (Risher et 
al., 2014). The difference in spine shape may represent the different maturation states 
(Berry and Nedivi, 2017). Mushroom shaped spines and thin spines have similar shape. 
Both of them have large bulbous head, but Mushroom spines have relative narrow neck 
and thin spines have a long neck. Stubby spines are lack a distinctive head and neck 
configuration. Filopodia are the smallest hair-like structures protruding from dendrites, 
often described as immature spines (Berry and Nedivi, 2017). However, whether spines 
with different sizes serve distinct functions is not yet clear. In Sez6-/- mice, the densities 
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of stubby, thin and mushroom spines decrease. However, filopodia do not show changes. 
It might be indicated that the maturation of new spines is not impaired.  
 
 
Figure 27: Schematic diagram of spine morphological categories 
Base on their morphology, dendritic protrusions has been group into 4 types. Mushroom 
shaped spine has a large bulbous head and a relative narrow neck. Thin spines have 
similar shape, but smaller head and long neck. Stubby spine is lack of a distinctive head 
and neck. Filopodia are the thinnest hair-like structures (Risher et al., 2014). 
 
Then we tested whether SEZ6 involved into regulating spine plasticity. It is also known as 
structural plasticity which is the consequence of structural changes in the number and 
shape of dendritic spines (Fu and Zuo, 2011). New spine formation is the structural base 
of memory consolidation (van der Zee, 2015) and reduced spine density is commonly 
seen in neurodegenerative diseases (Berry and Nedivi, 2017; Bittner et al., 2012; 
Hoffmann et al., 2013; Zou et al., 2016). To our surprised in standard housing condition, 
the fractions of new gained and lost spines do not show any changes compared to WT 
control. Then the enriched environmental (EE) condition was applied to Sez6-/- mice. EE 
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is an experimental setting in which is housing in an environment with complex of cognitive, 
motor and social stimulation. It is commonly used to boost dendritic spine turnover. Some 
spine density reduction and synaptic functional deficits were about to be recused by EE 
(Morelli et al., 2014). Consistent with our previous finding, the dendritic spine density 
increased in control mice shortly after entering EE cages (Jung and Herms, 2014). Since 
the expression of SEZ6 is highly dependent on the neuronal activity and Sez6 mRNA 
level significantly increased in neuronal cortex and naïve mouse after EE (Anderson et 
al., 2012; Rampon et al., 2000), indicating that any activity induced alteration might 
affected. Indeed, Sez6-/- mice started to show impaired dendritic spine plasticity in EE 
condition which is the spine density and new gained spine do not increase as control 
mice. 
Dendritic spines are the excitatory postsynaptic compartments, which receive and 
integrate information from pre-synaptic inputs (Yuste and Bonhoeffer, 2001). To correlate 
the intravital microscopic findings with electrophysiological functional properties, we 
performed hippocampal field recordings using age-matched WT and Sez6-/- mice, as well 
as EE stimulated Sez6-/- mice and controls. We tested the Schaffer collateral-CA1 
pathway. Since SEZ6 is mainly located in the somatodendritic compartment of neurons, 
which is in line with our findings that pre-synaptic function was not affected by the lack of 
SEZ6. But Sez6-/- mice showed impaired synaptic transmission, which might be the 
consequence of reduced dendritic spine density. Deceased LTP is also shown in Sez6-/- 
mice, which is consistent with defects in hippocampus-dependent memory (Gunnersen 
et al., 2007). EE improves a variety of hippocampal-dependent functions compared to 
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standard housing. We observed that LTP is significantly increased in WT control mice, 
but not in Sez6-/- mice after EE stimulation. Since hippocampal dendrites undergo 
spinogenesis after LTP induction (Nägerl et al., 2004, 2007), the observed LTP deficit in 
Sez6-/- mice may due to an impaired activity dependent dendritic spine plasticity. In 
addition, SEZ6 involves into neuronal activity in an NMDA-receptor dependent manner 
(Havik et al., 2007; Shimizu-Nishikawa et al., 1995a), which may also explain that SEZ6 
is functionally involved in LTP maintenance.  
In summary, we provide several new insights into the physiological roles of SEZ6 in the 
adult brain in this study. 1) we showed that SEZ6 involved into regulating dendritic spine 
density in a dose dependent manner; 2) SEZ6 involved into regulating the maturation of 
new spines; 3) SEZ6 involved into regulating synaptic functional plasticity; 4) SEZ6 
involved in regulating dendritic spine plasticity in complex stimulation condition. 
2. BACE1 inhibition impairs synaptic structure and function via SEZ6  
As the most common form of senile dementia, AD is a significant challenge to healthcare 
systems worldwide. Currently, the promising potential therapeutic strategies are: 1) 
prevention of Aβ production by inhibiting or modulating the amyloid cascade enzymes, 
BACE1 and γ-secretase complex with small molecules (Huang and Mucke, 2012; 
Neumann et al., 2015; Yuan et al., 2013); 2) enhancing clearance of Aβ or amyloid 
plaques by immunotherapies (Doody et al., 2014; Salloway et al., 2014); 3) prevention of 
Aβ aggregation (Ryan et al., 2015). Unfortunately, the outcomes of γ-secretase inhibitor 
trials were disappointing because too many important signaling cascades, including 
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Notch signaling, are affected by chronic inhibition of the γ-secretase complex (Bittner et 
al., 2009; De Strooper, 2014). Immunotherapy studies have shown only marginal disease 
modification, although it has been reported that Aβ antibody treatment benefits a subset 
of patients in the early stages of disease progression (Reardon, 2015). BACE1 is another 
very attractive therapeutic target, mainly because 1) it initiates the amyloidogenic cascade 
(Lin et al., 2000), 2) Bace1 knockout mice are viable and fertile (Cai et al., 2001), 3) the 
pathological hallmarks of AD, such as high Aβ load, plaque deposition and 
electrophysiological dysfunction, are largely prevented in BACE1 null APP transgenic 
mice (Luo et al., 2001; Ohno et al., 2004), and 4) BACE1 activity can be blocked by small 
molecules (May et al., 2011; Neumann et al., 2015; Stamford et al., 2012). Several 
BACE1 inhibitors are currently in AD clinical trials (Godyń et al., 2016; May et al., 2011). 
However, BACE1 inhibition interferes structural and functional synaptic plasticity in mice 
(Filser et al., 2015). This may be due to inhibition of BACE1 processing of several its 
physiological substrates, which would then lead to on-target side effects. 
Although BACE1 has many substrates, We hypothesized that BACE1-inhibition-induced 
structural and functional synaptic alterations could be due to disruption of the SEZ6 
function for the following reasons: SEZ6 is predominantly processed by BACE1 (Kuhn et 
al., 2012) and Sez6 null mice display certain similar deficits compared to BACE1 inhibited 
(Filser et al., 2015) or knockout mice (Laird et al., 2005), including reduced cortical neuron 
dendritic spine density and diminished performance in hippocampal-dependent 
behavioral tests (Gunnersen et al., 2007). 
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We used chronic intravital microscopy and electrophysiological field recordings to study 
NB-360 treated WT and Sez6 knockout mice. NB-360 blocked BACE1 activity almost 
completely, similar to the effects of high-doses of BACE1 inhibitors SCH1682496 and 
LY2811376 (Filser et al., 2015; May et al., 2011; Stamford et al., 2012). We also observed 
that NB-360 interfered with structural and functional synaptic plasticity in WT mice. Since 
three structurally different BACE1 inhibitors (NB-360, SCH1682496 and LY2811376) 
influenced dendritic spine plasticity and hippocampal LTP in a similar way, off-target 
effects are rather unlikely (Filser et al., 2015; Killick et al., 2015). Unlike in WT mice, both 
dendritic spine density and plasticity were not affected by chronic NB-360 treatment 
suggesting that SEZ6 is involved in BACE1-inhibition-induced spine alterations. However, 
Sez6-/- mice show developmental deficits like neurite branching alterations during 
development and Sez6 knockdown neurons show altered calcium activity (Anderson et 
al., 2012; Gunnersen et al., 2007). To rule out developmental deficits, we applied NB-360 
to conditional knockout (Sez6cKO/cKO) mice. NB-360 treatment did not alter dendritic spine 
plasticity in Sez6cKO neurons. Thus, we conclude that cell autonomous membrane-bound 
SEZ6 protein contributes to this structural synaptic alteration. Taken together, these data 
indicate that BACE1-inhibition-induced structural plasticity is via SEZ6. 
BACE1 is a negative regulator of SEZ6 cell surface level (Pigoni et al., 2016). The detail 
mechanism of accumulated SEZ6 affects dendritic spine density and plasticity is not yet 
clear. SEZ6 contains 7 protein-protein interaction domains: 5 short consensus repeat 
(SCR) domains and 2 complement subcomponent C1r, C1s/sea urchin embryonic growth 
factor Uegf/bone morphogenetic protein 1 (CUB) domains (Gunnersen et al., 2007). Both 
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of SCR and CUB domains are considered to associate with complement proteins (Bork 
and Beckmann, 1993; Mizukami et al., 2016). It is known that complement signal 
cascaded is an important inducer for synaptic pruning in both physiological condition and 
AD cases (151-153). Full-length SEZ6 accumulated at the cell membrane of post-synaptic 
compartment upon BACE1 inhibition (Gunnersen et al., 2007; Zhu et al., 2018). It is 
interesting to study whether accumulated SEZ6 would induce synaptic pruning by 
recruiting complement protein to synapses. 
Dendritic spines are the excitatory postsynaptic compartments, which receive and 
integrate information from pre-synaptic inputs (Yuste and Bonhoeffer, 2001). In order to 
correlate the intravital microscopic findings with electrophysiological functional properties, 
we performed hippocampal field recordings using brain slices from 3-week NB-360 
treated age-matched WT and Sez6-/- mice, as well as vehicle treated controls. Sez6-/- 
mice showed impaired Schaffer collateral-CA1 LTP, which is consistent with previous 
data. Chronic BACE1 inhibition does not attenuate this further, indicating that SEZ6 is 
involved in BACE1-inhibition-induced reduction in synaptic plasticity. Since hippocampal 
dendrites undergo spinogenesis after LTP induction (Nägerl et al., 2004, 2007), the 
observed LTP attenuation may be due to an impaired dendritic spine plasticity, consistent 
with the overall decrease in spine density, smaller EPSCs seen in Sez6-/- mice 
(Gunnersen et al., 2007) and the reduced spine density observed in BACE1 inhibitor-
treated WT mice. In addition, Sez6 mRNA levels are increased after strong neuronal 
activity (Shimizu-Nishikawa et al., 1995a) and this was shown to occur in an NMDA-
receptor dependent manner (Havik et al., 2007), which may imply that SEZ6 is 
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functionally involved in LTP maintenance. SEZ6 is mainly located in the dendritic and 
somatic compartment of neurons (Gunnersen et al., 2007), which is in line with our 
findings that pre-synaptic function was not affected by the lack of SEZ6. Surprisingly, pre-
synaptic deficits were not observed in NB-360 treated WT mice, although BACE1 
accumulates in pre-synaptic terminals (Hitt et al., 2012; Kandalepas et al., 2013) and 
Bace1 knockout mouse neurons display a severe pre-synaptic dysfunction at the mossy 
fiber terminals (Wang et al., 2008, 2014). This may due to differences in the 
developmental trajectory of gene knockout-induced phenotypes compared to inhibitor 
treatment of adult mice and/or due to the different brain regions studied.  
Other indirect consequences of BACE1 inhibition on synaptic plasticity have to be 
considered. Willem and colleagues reported a novel APP cleavage pathway, which 
involved MT-MMP to generate Aη-α/β. After BACE1 inhibition, the Aη-α significantly 
elevated due to more MT-MMP cleavage products go through the anti-amyloidogenic 
pathway. By acutely applying Aη-α in bath they observed a significant attenuation of 
hippocampal LTP, as well as reduced neuronal activity (Willem et al., 2015). However, 
another APP metabolites soluble APP alpha (sAPPα) also accumulates upon BACE1 
inhibition (Fukumoto et al., 2010; Neumann et al., 2015), sAPPα has considerable 
neuroprotective and neurotrophic functions, including rescuing LTP deficits in the AD 
mouse (Fol et al., 2015). The precise mechanism of how sAPPα and Aη-α influences 
synaptic plasticity is not yet clear. Further studies are needed to clarify how APP cleavage 
products affect functional synaptic plasticity in physiological levels, and under 
pharmacological BACE1 inhibition.  
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BACE1 inhibitors prevent amyloid plaque formation AD models which strongly support 
the notion that BACE1 inhibitor treatments can be considered as a promising therapeutic 
approach for AD. But synaptic deficits which are observed upon strong BACE1 inhibition 
in WT mice may limit the usage of BACE1 inhibitors as a therapeutic approach for AD. It 
does not mean that we need to move on from BACE1 inhibition treatment. BACE1 
inhibition induced synaptic deficits are only observed in condition of strongly suppressed 
the BACE1 proteolytic activity (Filser et al., 2015; Savonenko et al., 2008; Wang et al., 
2014). Therefore, identifying the optimal dosage, which could balance BACE1 inhibition, 
induced synaptic deficits and Aβ induced impairments, is urgent. Establishing a reliable 
and appropriate method such identifying a few reliable biomarkers might be the most 
feasible approach. BACE1 CSF levels has been showed strong correlations to Aβ level, 
and it has been considered as biomarker for AD (Ewers et al., 2008, 2011; Holsinger et 
al., 2004; Pera et al., 2013; Shen et al., 2017; Timmers et al., 2017). But it may not 
represent whether the fundamental synaptic function is impaired by inhibitor treatment. 
Ore data suggested that the optimal dosing in order to avoid synaptic side effects could 
be potentially achieved by monitoring the levels of SEZ6 cleavage products in the CSF 
on an individual basis, because 1) BACE1 derived SEZ6 cleavage products can be 
measured in body fluids (Khoonsari et al., 2016; Maccarrone et al., 2013; Pigoni et al., 
2016), 2) SEZ6 is closely related to the structure and function of synapses and 3) BACE1-
inhibition induced synaptic impairment is via altered process of SEZ6. Future studies are 
expected to provide more knowledge regarding the biological functions of BACE1 and 
safety of BACE1 inhibition approach in mouse models and AD patients. 
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°C degree celcius 
μg microgram 
μl microliter 
μl micrometer 
Aβ amyloid beta 
AD Alzheimer's disease 
ANOVA analysis of variance 
APP amyloid precurser protein 
BACE1 Beta-site amyloid precursor protein cleaving enzyme 1 
CA1 Cornu Ammonis 1 
CA3 Cornu Ammonis 3 
dpi days post-injection 
CNS central nervous system 
e.g. lat. exempli gratia; for example 
eGFP enhanced greed 
et al. and others 
ER endoplasmatic reticulum 
FAD familial Alzheimer's disease 
Fig. Figure 
g gram 
h hour 
Hz Hertz 
kDa kilodalton 
KO knock out 
LTD long-term depression 
LTP long-term potentiation 
M molar 
mg milligram 
min minute 
ml milliliter 
mm millimeter 
mM millimolar 
MW molecular weight 
NaCl sodium chloride 
NaHCO3 sodium bicarbonate 
NGS normal goat serum 
nm nanometer 
NMDA N-methyl-D-aspartate 
P p-value 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
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ROI region of interest 
PSD Post-synaptic density 
rpm revolutions per minute 
s second 
SD standard deviation 
SEM standard error of the mean 
t time 
Ti:Sa lasing medium; sapphire crystal, doped with titanium ions 
Tab. Table 
tg transgene 
Thy1 thymus cell antigen 1 
TOR turnover ratio 
WT wild type 
YFP yellow fluorescence protein 
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